drug_name,age,sex,weight,disease_status,dosage,dose_duration,comorbidities,lifestyle_factors,pregnancy,pregnancy_month,ast(10-40),alt(5-30),alp(150-280),adr,symptoms,suggestions,genetic_factors,pharmacokinetics,pharmacodynamics,drug_interactions,concomitant_medicine
Isoniazid,78,F,47kg,XDR-TB,235mg,6-9 months,HIV,Drug User,none,0,11,13,214,"Psychiatric Symptoms, GI Upset, CNS Effects","Irritability, Psychosis, Headache, Seizures, Diarrhea, Nausea, Abdominal pain, Dizziness, Confusion, Depression, Hallucinations, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,26,F,60kg,MDR-TB,300mg,6-9 months,Renal Disease,Alcoholic,yes,1,35,30,266,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,72,M,44kg,XDR-TB,440mg,6 months,none,Alcoholic,none,0,18,9,264,"GI Upset, Hepatotoxicity, Psychiatric Symptoms","Irritability, Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,35,F,61kg,Tuberculosis,600mg,6 months,Liver Disease,Drug User,yes,3,39,21,196,"CNS Effects, Psychiatric Symptoms, Blood Disorders","Anemia, Psychosis, Seizures, Headache, Thrombocytopenia, Leukopenia, Neutropenia, Eosinophilia, Dizziness, Confusion, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,17,M,46kg,Tuberculosis,230mg,6-9 months,Diabetes,none,none,0,31,19,258,"Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,29,F,81kg,Tuberculosis,486mg,11 months,Hypertension,Drug User,yes,4,36,11,160,"Peripheral Neuropathy, Optic Neuritis, Blood Disorders","Anemia, Tingling, Burning sensation, Muscle cramps, Weakness, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Vision loss",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,63,M,41kg,Tuberculosis,205mg,6-9 months,HIV,Drug User,none,0,22,18,227,"CNS Effects, Blood Disorders, Renal Toxicity","Anemia, Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Thrombocytopenia, Leukopenia, Neutropenia, Eosinophilia, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,16,M,67kg,XDR-TB,300mg,6-9 months,Cardiovascular Disease,Occasional Smoker,none,0,18,20,241,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Salbutamol
Ethambutol,36,F,67kg,MDR-TB,400mg,12 months,Diabetes,Alcoholic,none,0,32,6,247,"Peripheral Neuropathy, GI Upset, Psychiatric Symptoms","Irritability, Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Abdominal pain, Numbness, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,56,M,89kg,XDR-TB,300mg,6-9 months,Renal Disease,Alcoholic,none,0,39,12,196,"CNS Effects, GI Upset","Psychosis, Headache, Seizures, Diarrhea, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Isoniazid,28,M,80kg,XDR-TB,300mg,6-9 months,Renal Disease,none,none,0,32,16,225,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Rifampicin,23,M,90kg,MDR-TB,600mg,6 months,Liver Disease,Occasional Smoker,none,0,24,28,179,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,77,M,94kg,MDR-TB,477mg,11 months,Renal Disease,Drug User,none,0,15,7,253,"Peripheral Neuropathy, Blood Disorders, GI Upset","Anemia, Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Leukopenia, Nausea, Abdominal pain, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Pyrazinamide,78,F,93kg,XDR-TB,275mg,6 months,Hypertension,Alcoholic,none,0,38,19,181,"Peripheral Neuropathy, GI Upset, Blood Disorders","Anemia, Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Leukopenia, Abdominal pain, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Rifampicin,25,F,70kg,Tuberculosis,600mg,6 months,HIV,Smoker,none,0,19,25,247,"Hypersensitivity Reactions, Renal Toxicity, Hepatotoxicity","Anaphylaxis, Hematuria, Jaundice, Joint pain, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,41,M,84kg,MDR-TB,600mg,6 months,Anemia,none,none,0,11,19,237,"Hypersensitivity Reactions, Blood Disorders","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,none,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Pyrazinamide,61,F,76kg,Tuberculosis,268mg,8 months,Liver Disease,Drug User,yes,8,34,19,233,"Renal Toxicity, GI Upset, CNS Effects","Hematuria, Psychosis, Headache, Proteinuria, Seizures, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,46,M,39kg,MDR-TB,390mg,6 months,none,none,none,0,10,7,256,"Hypersensitivity Reactions, CNS Effects, Peripheral Neuropathy","Anaphylaxis, Joint pain, Burning sensation, Psychosis, Tingling, Headache, Seizures, Muscle cramps, Swelling, Weakness, Dizziness, Fever, Numbness, Skin rashes, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,47,M,72kg,MDR-TB,297mg,7 months,none,Smoker,none,0,33,14,248,"GI Upset, Hepatotoxicity, Blood Disorders","Anemia, Diarrhea, Nausea, Leukopenia, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Vomiting, Neutropenia, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,12,F,99kg,MDR-TB,600mg,6 months,HIV,Occasional Smoker,none,0,13,22,272,"Optic Neuritis, Blood Disorders, Peripheral Neuropathy","Anemia, Tingling, Burning sensation, Leukopenia, Muscle cramps, Weakness, Blurry vision, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,66,F,64kg,XDR-TB,303mg,9 months,HIV,Occasional Smoker,none,0,27,8,228,"CNS Effects, Psychiatric Symptoms","Psychosis, Seizures, Headache, Dizziness, Confusion, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,41,M,73kg,MDR-TB,512mg,7 months,HIV,Smoker,none,0,12,14,215,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,64,F,49kg,MDR-TB,490mg,6 months,Liver Disease,Alcoholic,none,0,40,6,207,"Optic Neuritis, Blood Disorders","Anemia, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,61,M,40kg,Tuberculosis,400mg,6 months,Renal Disease,Smoker,none,0,24,29,168,"Renal Toxicity, Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,24,M,59kg,Tuberculosis,295mg,6-9 months,Diabetes,none,none,0,12,25,277,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,70,M,75kg,XDR-TB,508mg,12 months,Diabetes,none,none,0,18,9,239,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,45,F,32kg,MDR-TB,355mg,10 months,Hypertension,Smoker,yes,1,23,8,171,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,76,F,56kg,MDR-TB,492mg,10 months,Anemia,Occasional Smoker,none,0,25,9,192,"Blood Disorders, Peripheral Neuropathy, CNS Effects","Anemia, Tingling, Burning sensation, Psychosis, Seizures, Headache, Leukopenia, Weakness, Muscle cramps, Confusion, Dizziness, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,20,M,66kg,Tuberculosis,300mg,6-9 months,none,Smoker,none,0,35,6,241,"Optic Neuritis, Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,18,M,37kg,XDR-TB,485mg,8 months,Anemia,Occasional Smoker,none,0,37,7,242,"Blood Disorders, Renal Toxicity, Peripheral Neuropathy","Anemia, Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Leukopenia, Muscle cramps, Weakness, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Ethambutol,49,M,86kg,Tuberculosis,375mg,8 months,none,Occasional Smoker,none,0,35,15,182,"Optic Neuritis, Blood Disorders, GI Upset","Anemia, Diarrhea, Leukopenia, Nausea, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,63,M,80kg,XDR-TB,600mg,6 months,none,Drug User,none,0,36,11,170,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,15,F,81kg,XDR-TB,252mg,7 months,none,Smoker,none,0,20,17,226,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,49,F,77kg,Tuberculosis,542mg,6 months,Renal Disease,Smoker,none,0,26,27,258,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Isoniazid,38,F,94kg,Tuberculosis,300mg,6-9 months,Liver Disease,none,none,0,21,7,249,"Optic Neuritis, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,52,M,33kg,XDR-TB,165mg,6-9 months,Diabetes,Occasional Smoker,none,0,33,13,159,"Peripheral Neuropathy, Hepatotoxicity","Tingling, Burning sensation, Muscle cramps, Weakness, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Numbness, Vomiting",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Ethambutol,15,M,85kg,Tuberculosis,155mg,11 months,Renal Disease,none,none,0,40,19,152,"GI Upset, CNS Effects, Renal Toxicity","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Rifampicin,61,M,58kg,XDR-TB,580mg,6 months,Anemia,Alcoholic,none,0,37,20,250,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Isoniazid,19,M,57kg,XDR-TB,285mg,6-9 months,Anemia,none,none,0,35,24,228,"Hypersensitivity Reactions, Peripheral Neuropathy, Optic Neuritis","Anaphylaxis, Joint pain, Tingling, Burning sensation, Muscle cramps, Swelling, Weakness, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,47,M,63kg,XDR-TB,300mg,6-9 months,none,none,none,0,10,24,226,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,52,M,56kg,Tuberculosis,352mg,12 months,Anemia,Alcoholic,none,0,10,8,270,"Renal Toxicity, Hepatotoxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,38,M,76kg,Tuberculosis,600mg,6 months,none,Smoker,none,0,13,24,260,"Psychiatric Symptoms, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,43,F,55kg,XDR-TB,275mg,6-9 months,Hypertension,Occasional Smoker,none,0,37,17,232,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,40,F,90kg,MDR-TB,600mg,6 months,HIV,Occasional Smoker,yes,5,20,9,209,"Renal Toxicity, GI Upset","Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,77,F,70kg,MDR-TB,468mg,7 months,HIV,Alcoholic,none,0,38,28,216,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,61,F,69kg,MDR-TB,600mg,6 months,HIV,Smoker,yes,5,11,23,254,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,46,M,50kg,XDR-TB,313mg,6 months,Liver Disease,Drug User,none,0,28,28,231,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,60,M,64kg,MDR-TB,300mg,6-9 months,Renal Disease,none,none,0,38,17,268,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Isoniazid,39,M,36kg,MDR-TB,180mg,6-9 months,Renal Disease,Smoker,none,0,39,25,229,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,65,M,30kg,MDR-TB,150mg,6-9 months,Anemia,Occasional Smoker,none,0,15,22,155,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,11,M,93kg,XDR-TB,600mg,6 months,Renal Disease,Smoker,none,0,16,6,161,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Isoniazid,23,F,47kg,MDR-TB,235mg,6-9 months,Liver Disease,none,none,0,38,8,170,"Hypersensitivity Reactions, Peripheral Neuropathy, Optic Neuritis","Anaphylaxis, Joint pain, Burning sensation, Tingling, Muscle cramps, Swelling, Weakness, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Rifampicin,59,M,100kg,XDR-TB,600mg,6 months,none,Smoker,none,0,23,27,214,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Ethambutol,46,F,33kg,XDR-TB,341mg,8 months,Renal Disease,Alcoholic,none,0,40,16,160,"Psychiatric Symptoms, Optic Neuritis, Hepatotoxicity","Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Depression, Jaundice, Vomiting, Vision loss, Hallucinations, Irritability",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,47,F,82kg,MDR-TB,300mg,6-9 months,Diabetes,Drug User,yes,1,11,13,248,"Renal Toxicity, Hepatotoxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Pyrazinamide,36,M,76kg,Tuberculosis,133mg,6 months,Liver Disease,Smoker,none,0,36,25,228,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,41,F,92kg,XDR-TB,600mg,6 months,Hypertension,Alcoholic,none,0,38,20,229,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,61,M,98kg,XDR-TB,555mg,7 months,Anemia,Occasional Smoker,none,0,14,9,206,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,44,M,80kg,XDR-TB,363mg,11 months,Renal Disease,none,none,0,10,15,192,"Peripheral Neuropathy, Optic Neuritis, Hepatotoxicity","Tingling, Burning sensation, Muscle cramps, Weakness, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Numbness, Vomiting, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,12,F,31kg,Tuberculosis,310mg,6 months,none,Smoker,yes,2,39,16,265,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Ethambutol,39,F,52kg,XDR-TB,259mg,10 months,Anemia,none,Pregnant - 7 months,2,15,12,166,"GI Upset, Blood Disorders, Optic Neuritis","Anemia, Diarrhea, Nausea, Leukopenia, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,50,M,53kg,MDR-TB,109mg,7 months,Diabetes,Smoker,none,0,16,5,207,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Rifampicin,31,F,89kg,MDR-TB,600mg,6 months,Hypertension,Occasional Smoker,none,0,12,6,210,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Isoniazid,46,F,91kg,Tuberculosis,300mg,6-9 months,Hypertension,Smoker,none,0,14,23,155,"CNS Effects, Blood Disorders","Anemia, Psychosis, Seizures, Headache, Thrombocytopenia, Leukopenia, Neutropenia, Eosinophilia, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,63,M,88kg,XDR-TB,600mg,6 months,none,Drug User,none,0,15,26,264,"Peripheral Neuropathy, Optic Neuritis","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,51,M,77kg,MDR-TB,528mg,6 months,none,none,none,0,40,29,190,"Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,30,F,69kg,Tuberculosis,300mg,6-9 months,Liver Disease,Alcoholic,yes,1,34,27,262,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Monitor liver function tests regularly; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Isoniazid,48,M,95kg,Tuberculosis,300mg,6-9 months,HIV,Drug User,none,0,11,22,185,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,21,M,57kg,MDR-TB,285mg,6-9 months,HIV,Smoker,none,0,35,14,176,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,25,F,89kg,XDR-TB,192mg,11 months,Liver Disease,Alcoholic,Pregnant - 7 months,5,11,15,198,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Ethambutol,80,F,53kg,XDR-TB,422mg,12 months,Anemia,none,yes,7,23,11,204,"Optic Neuritis, GI Upset, CNS Effects","Psychosis, Seizures, Headache, Diarrhea, Nausea, Blurry vision, Abdominal pain, Dizziness, Confusion, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,35,F,54kg,Tuberculosis,270mg,6-9 months,none,Drug User,yes,2,34,16,199,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Ethambutol,33,M,92kg,MDR-TB,441mg,10 months,HIV,Drug User,none,0,29,7,273,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Pyrazinamide,25,F,60kg,Tuberculosis,447mg,7 months,HIV,none,none,0,31,27,190,"Hypersensitivity Reactions, GI Upset, CNS Effects","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Diarrhea, Nausea, Swelling, Abdominal pain, Dizziness, Fever, Skin rashes, Confusion, Loss of appetite",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,76,F,86kg,MDR-TB,300mg,6-9 months,Hypertension,Occasional Smoker,none,0,22,15,267,"CNS Effects, Optic Neuritis","Psychosis, Seizures, Headache, Blurry vision, Dizziness, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Ethambutol,21,M,84kg,MDR-TB,371mg,8 months,HIV,Alcoholic,none,0,26,19,197,"Hypersensitivity Reactions, Psychiatric Symptoms","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,14,M,50kg,XDR-TB,250mg,6-9 months,Liver Disease,Drug User,none,0,20,21,203,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Rifampicin,30,M,36kg,XDR-TB,360mg,6 months,HIV,Smoker,none,0,25,21,228,"Optic Neuritis, GI Upset","Diarrhea, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,65,M,54kg,Tuberculosis,247mg,8 months,none,Drug User,none,0,13,22,157,"CNS Effects, Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Psychosis, Seizures, Headache, Thrombocytopenia, Leukopenia, Swelling, Neutropenia, Eosinophilia, Dizziness, Fever, Skin rashes, Confusion",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Ethambutol,15,M,61kg,Tuberculosis,384mg,8 months,Hypertension,Alcoholic,none,0,16,24,228,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,34,M,50kg,Tuberculosis,500mg,6 months,Liver Disease,Alcoholic,none,0,21,28,272,"Psychiatric Symptoms, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,74,M,53kg,Tuberculosis,265mg,6-9 months,Anemia,none,none,0,14,30,248,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Rifampicin,12,F,82kg,XDR-TB,600mg,6 months,Anemia,Drug User,none,0,20,19,157,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Isoniazid,71,F,85kg,MDR-TB,300mg,6-9 months,Anemia,Drug User,yes,6,21,10,264,"Peripheral Neuropathy, Hepatotoxicity, Optic Neuritis","Tingling, Burning sensation, Muscle cramps, Weakness, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Numbness, Vomiting, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,60,F,47kg,XDR-TB,470mg,6 months,Hypertension,none,none,0,26,8,279,"Optic Neuritis, Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Ethambutol,77,F,74kg,MDR-TB,167mg,10 months,Renal Disease,Drug User,none,0,15,20,165,"GI Upset, Optic Neuritis, Blood Disorders","Anemia, Diarrhea, Nausea, Leukopenia, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,79,M,97kg,MDR-TB,379mg,6 months,Diabetes,Smoker,none,0,28,29,217,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Ethambutol,42,F,45kg,XDR-TB,316mg,7 months,Hypertension,Drug User,none,0,24,15,270,"Hypersensitivity Reactions, Optic Neuritis, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,71,M,54kg,XDR-TB,270mg,6-9 months,Hypertension,Smoker,none,0,40,28,187,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,79,F,51kg,MDR-TB,510mg,6 months,Hypertension,Drug User,yes,8,14,20,211,"Hypersensitivity Reactions, Psychiatric Symptoms","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Rifampicin,46,F,34kg,XDR-TB,340mg,6 months,none,Occasional Smoker,yes,3,30,5,171,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,22,M,39kg,XDR-TB,195mg,6-9 months,Liver Disease,Drug User,none,0,30,13,170,"Psychiatric Symptoms, Hepatotoxicity, Peripheral Neuropathy","Tingling, Burning sensation, Vomiting, Nausea, Weakness, Muscle cramps, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,71,M,67kg,MDR-TB,186mg,8 months,HIV,Alcoholic,none,0,39,26,225,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Isoniazid,34,M,64kg,XDR-TB,300mg,6-9 months,Diabetes,Alcoholic,none,0,21,28,249,"Optic Neuritis, Renal Toxicity, GI Upset","Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,34,M,53kg,XDR-TB,265mg,6-9 months,Renal Disease,Alcoholic,none,0,26,14,229,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,77,F,33kg,MDR-TB,568mg,9 months,Diabetes,none,none,0,36,8,204,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Ethambutol,52,F,36kg,MDR-TB,367mg,6 months,none,Smoker,none,0,36,13,277,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,37,F,72kg,XDR-TB,506mg,10 months,Hypertension,Smoker,yes,6,35,6,159,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Isoniazid,26,F,69kg,MDR-TB,300mg,6-9 months,Renal Disease,Smoker,yes,2,12,12,261,"GI Upset, Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Diarrhea, Nausea, Muscle cramps, Weakness, Blurry vision, Abdominal pain, Numbness, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Rifampicin,47,M,31kg,Tuberculosis,310mg,6 months,none,Smoker,none,0,37,26,156,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,51,M,58kg,MDR-TB,290mg,6-9 months,HIV,Alcoholic,none,0,14,26,232,"Hypersensitivity Reactions, Renal Toxicity, CNS Effects","Anaphylaxis, Hematuria, Joint pain, Psychosis, Headache, Proteinuria, Seizures, Kidney dysfunction, Swelling, Dizziness, Fever, Skin rashes, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,21,M,69kg,XDR-TB,596mg,10 months,Hypertension,Alcoholic,none,0,31,24,216,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,61,M,71kg,XDR-TB,298mg,9 months,Renal Disease,Drug User,none,0,29,6,255,"GI Upset, Blood Disorders, Optic Neuritis","Anemia, Diarrhea, Leukopenia, Nausea, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),none
Rifampicin,65,F,37kg,MDR-TB,370mg,6 months,Liver Disease,Smoker,yes,3,23,14,216,"CNS Effects, Hepatotoxicity","Psychosis, Vomiting, Headache, Seizures, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Pyrazinamide,62,M,54kg,MDR-TB,516mg,12 months,none,Smoker,none,0,36,25,161,"Renal Toxicity, Hypersensitivity Reactions, CNS Effects","Anaphylaxis, Hematuria, Joint pain, Psychosis, Headache, Proteinuria, Seizures, Kidney dysfunction, Swelling, Dizziness, Fever, Skin rashes, Confusion",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Pyrazinamide,62,F,62kg,MDR-TB,108mg,11 months,HIV,Alcoholic,yes,9,29,13,211,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,54,F,66kg,XDR-TB,300mg,6-9 months,HIV,Alcoholic,yes,5,32,10,224,"Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Isoniazid,16,F,35kg,MDR-TB,175mg,6-9 months,Liver Disease,Alcoholic,yes,9,16,12,230,"GI Upset, CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Seizures, Headache, Diarrhea, Nausea, Weakness, Muscle cramps, Abdominal pain, Dizziness, Numbness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,41,M,43kg,Tuberculosis,430mg,6 months,none,Occasional Smoker,none,0,14,8,165,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,38,M,76kg,Tuberculosis,361mg,10 months,Anemia,Smoker,none,0,39,16,169,"Renal Toxicity, Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,80,F,94kg,MDR-TB,300mg,6-9 months,Renal Disease,Alcoholic,none,0,20,21,178,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Isoniazid,15,F,44kg,XDR-TB,220mg,6-9 months,Hypertension,Drug User,yes,1,38,29,256,"CNS Effects, Renal Toxicity, Optic Neuritis","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Blurry vision, Dizziness, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,72,M,91kg,MDR-TB,600mg,6 months,Anemia,Smoker,none,0,40,5,250,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Rifampicin,65,F,88kg,MDR-TB,600mg,6 months,none,Drug User,none,0,30,6,185,"Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Ethambutol,39,F,36kg,XDR-TB,376mg,6 months,HIV,Smoker,none,0,24,19,247,"Optic Neuritis, Blood Disorders","Anemia, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,44,F,60kg,Tuberculosis,179mg,11 months,Anemia,Smoker,none,0,40,18,254,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Isoniazid,32,F,94kg,MDR-TB,300mg,6-9 months,Diabetes,Drug User,yes,8,26,22,160,"CNS Effects, Psychiatric Symptoms","Psychosis, Seizures, Headache, Dizziness, Confusion, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,73,M,41kg,XDR-TB,205mg,6-9 months,none,Drug User,none,0,13,10,252,"Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,56,M,58kg,XDR-TB,324mg,10 months,Diabetes,Alcoholic,none,0,36,7,268,"Peripheral Neuropathy, Optic Neuritis, GI Upset","Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Blurry vision, Abdominal pain, Numbness, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,75,M,91kg,Tuberculosis,600mg,6 months,Liver Disease,Alcoholic,none,0,37,6,195,"Hypersensitivity Reactions, Blood Disorders, Optic Neuritis","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Blurry vision, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Vision loss",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,65,M,65kg,MDR-TB,300mg,6-9 months,Hypertension,Alcoholic,none,0,24,16,262,"Hypersensitivity Reactions, GI Upset, Blood Disorders","Anaphylaxis, Anemia, Joint pain, Diarrhea, Nausea, Swelling, Leukopenia, Abdominal pain, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,17,M,40kg,MDR-TB,400mg,6 months,Liver Disease,Alcoholic,none,0,10,15,186,"Optic Neuritis, Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Blurry vision, Abdominal pain, Fever, Skin rashes, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,73,F,81kg,MDR-TB,445mg,10 months,Hypertension,Drug User,yes,4,23,16,216,"Peripheral Neuropathy, Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,80,F,45kg,XDR-TB,129mg,11 months,Diabetes,Drug User,yes,2,24,7,199,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),none
Pyrazinamide,36,M,61kg,XDR-TB,116mg,8 months,Renal Disease,Drug User,none,0,40,25,188,"Peripheral Neuropathy, Psychiatric Symptoms","Tingling, Burning sensation, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,67,M,98kg,MDR-TB,300mg,6-9 months,Hypertension,Smoker,none,0,17,30,185,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Rifampicin,67,M,92kg,Tuberculosis,600mg,6 months,HIV,none,none,0,24,19,278,"CNS Effects, GI Upset, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Diarrhea, Nausea, Swelling, Abdominal pain, Dizziness, Fever, Skin rashes, Confusion, Loss of appetite",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Isoniazid,77,M,83kg,Tuberculosis,300mg,6-9 months,Renal Disease,Smoker,none,0,11,15,247,"Blood Disorders, GI Upset","Anemia, Diarrhea, Leukopenia, Nausea, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,13,M,51kg,MDR-TB,246mg,7 months,none,none,none,0,21,20,158,"Psychiatric Symptoms, Blood Disorders, Hepatotoxicity","Anemia, Leukopenia, Nausea, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Vomiting, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Pyrazinamide,59,F,56kg,MDR-TB,572mg,11 months,Hypertension,Drug User,none,0,21,10,225,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,72,F,33kg,XDR-TB,296mg,11 months,Diabetes,Occasional Smoker,none,0,23,14,204,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Isoniazid,22,M,84kg,Tuberculosis,300mg,6-9 months,HIV,Drug User,none,0,26,13,207,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,69,M,47kg,XDR-TB,235mg,6-9 months,Renal Disease,Occasional Smoker,none,0,32,16,247,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,33,F,41kg,MDR-TB,192mg,8 months,Diabetes,Drug User,yes,7,39,6,248,"CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Headache, Seizures, Muscle cramps, Weakness, Dizziness, Numbness, Confusion",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Pyrazinamide,12,F,92kg,MDR-TB,317mg,9 months,Hypertension,none,none,0,14,18,266,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,74,F,94kg,Tuberculosis,300mg,6-9 months,Liver Disease,Occasional Smoker,none,0,20,13,157,"CNS Effects, Renal Toxicity, Psychiatric Symptoms","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Dizziness, Confusion, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Rifampicin,23,M,94kg,Tuberculosis,600mg,6 months,Diabetes,Smoker,none,0,13,10,245,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,54,F,32kg,Tuberculosis,301mg,6 months,Diabetes,Smoker,yes,9,36,30,273,"Psychiatric Symptoms, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Rifampicin,60,F,69kg,XDR-TB,600mg,6 months,none,Smoker,none,0,34,5,230,"Optic Neuritis, Renal Toxicity, Psychiatric Symptoms","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Depression, Vision loss, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Isoniazid,44,M,79kg,Tuberculosis,300mg,6-9 months,HIV,Smoker,none,0,27,25,214,"Blood Disorders, Optic Neuritis, Peripheral Neuropathy","Anemia, Tingling, Burning sensation, Leukopenia, Weakness, Muscle cramps, Blurry vision, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,66,F,96kg,Tuberculosis,125mg,12 months,Liver Disease,Smoker,yes,8,10,29,232,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),none
Isoniazid,25,F,76kg,Tuberculosis,300mg,6-9 months,Diabetes,Occasional Smoker,none,0,25,30,222,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,12,F,57kg,XDR-TB,570mg,6 months,Diabetes,Drug User,yes,2,38,26,263,"Psychiatric Symptoms, Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,33,M,36kg,MDR-TB,360mg,6 months,Anemia,Alcoholic,none,0,21,28,220,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,15,M,33kg,Tuberculosis,165mg,6-9 months,Hypertension,Occasional Smoker,none,0,34,8,162,"Psychiatric Symptoms, Renal Toxicity, Hepatotoxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Rifampicin,28,M,33kg,MDR-TB,330mg,6 months,none,Alcoholic,none,0,23,25,226,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Pyrazinamide,51,F,98kg,XDR-TB,244mg,8 months,Liver Disease,Occasional Smoker,yes,6,23,15,215,"CNS Effects, GI Upset, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Seizures, Headache, Diarrhea, Nausea, Swelling, Abdominal pain, Dizziness, Fever, Skin rashes, Confusion, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,35,F,86kg,Tuberculosis,600mg,6 months,Anemia,Drug User,yes,8,12,12,209,"CNS Effects, Psychiatric Symptoms","Psychosis, Seizures, Headache, Dizziness, Confusion, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,10,F,67kg,MDR-TB,231mg,6 months,Anemia,Smoker,yes,5,24,8,204,"Optic Neuritis, Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,15,M,31kg,MDR-TB,310mg,6 months,none,none,none,0,19,8,210,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Ethambutol,59,M,40kg,Tuberculosis,321mg,10 months,HIV,none,none,0,13,23,247,"Hypersensitivity Reactions, Hepatotoxicity, Optic Neuritis","Anaphylaxis, Jaundice, Joint pain, Vomiting, Nausea, Swelling, Elevated liver enzymes, Blurry vision, Abdominal pain, Fever, Skin rashes, Vision loss",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Pyrazinamide,47,M,68kg,XDR-TB,198mg,8 months,Renal Disease,Smoker,none,0,19,22,251,"Optic Neuritis, Peripheral Neuropathy, GI Upset","Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Blurry vision, Abdominal pain, Numbness, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Isoniazid,55,M,32kg,MDR-TB,160mg,6-9 months,Renal Disease,Smoker,none,0,17,22,252,"Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,55,F,81kg,XDR-TB,300mg,6-9 months,Anemia,Drug User,yes,2,19,9,260,"Psychiatric Symptoms, Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Ethambutol,22,M,47kg,XDR-TB,365mg,7 months,Liver Disease,Drug User,none,0,13,21,248,"Optic Neuritis, CNS Effects","Psychosis, Headache, Seizures, Blurry vision, Dizziness, Confusion, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,34,M,52kg,XDR-TB,106mg,12 months,Liver Disease,Occasional Smoker,none,0,23,25,235,"Optic Neuritis, CNS Effects, GI Upset","Psychosis, Headache, Seizures, Diarrhea, Nausea, Blurry vision, Abdominal pain, Dizziness, Confusion, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,60,M,62kg,Tuberculosis,600mg,6 months,Hypertension,Alcoholic,none,0,32,11,268,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Ethambutol,20,M,66kg,MDR-TB,147mg,8 months,Diabetes,Occasional Smoker,none,0,27,10,170,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Isoniazid,75,M,53kg,XDR-TB,265mg,6-9 months,Liver Disease,Occasional Smoker,none,0,17,14,247,"Hepatotoxicity, Blood Disorders","Anemia, Vomiting, Nausea, Leukopenia, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,17,F,48kg,XDR-TB,480mg,6 months,Liver Disease,Alcoholic,yes,4,27,25,266,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,28,F,80kg,MDR-TB,597mg,12 months,Renal Disease,Drug User,yes,1,27,24,211,"Renal Toxicity, Blood Disorders","Hematuria, Anemia, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,40,F,41kg,Tuberculosis,199mg,9 months,Anemia,Alcoholic,none,0,32,11,162,"GI Upset, Psychiatric Symptoms","Irritability, Diarrhea, Nausea, Abdominal pain, Depression, Hallucinations, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,46,F,42kg,XDR-TB,348mg,6 months,Renal Disease,Smoker,Pregnant - 7 months,9,16,19,232,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,34,F,35kg,Tuberculosis,178mg,11 months,Anemia,Drug User,none,0,19,18,263,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,50,M,44kg,Tuberculosis,326mg,10 months,Renal Disease,Drug User,none,0,21,23,154,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,27,M,85kg,MDR-TB,300mg,6-9 months,Anemia,none,none,0,18,8,175,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Isoniazid,60,M,33kg,MDR-TB,165mg,6-9 months,Hypertension,none,none,0,18,30,207,"Hepatotoxicity, GI Upset","Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,34,F,92kg,MDR-TB,556mg,9 months,Hypertension,none,none,0,16,8,190,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,48,F,50kg,MDR-TB,500mg,6 months,Diabetes,Alcoholic,none,0,36,14,208,"Peripheral Neuropathy, CNS Effects, GI Upset","Tingling, Burning sensation, Psychosis, Headache, Seizures, Diarrhea, Muscle cramps, Weakness, Nausea, Abdominal pain, Dizziness, Numbness, Confusion, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,73,M,88kg,Tuberculosis,300mg,6-9 months,Hypertension,Occasional Smoker,none,0,31,13,279,"GI Upset, Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,76,F,79kg,MDR-TB,258mg,7 months,Anemia,Alcoholic,none,0,33,27,191,"Hypersensitivity Reactions, Peripheral Neuropathy","Anaphylaxis, Joint pain, Tingling, Burning sensation, Muscle cramps, Swelling, Weakness, Fever, Numbness, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Ethambutol,65,F,98kg,MDR-TB,538mg,10 months,none,Alcoholic,none,0,18,18,200,"CNS Effects, Optic Neuritis, Hepatotoxicity","Psychosis, Seizures, Headache, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Dizziness, Jaundice, Vomiting, Confusion, Vision loss",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,43,F,37kg,XDR-TB,554mg,9 months,Diabetes,Drug User,yes,4,18,18,253,"Renal Toxicity, Peripheral Neuropathy, Blood Disorders","Hematuria, Anemia, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Leukopenia, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Rifampicin,18,M,100kg,Tuberculosis,600mg,6 months,Hypertension,Occasional Smoker,none,0,31,25,249,"Hepatotoxicity, CNS Effects, Renal Toxicity","Hematuria, Psychosis, Vomiting, Headache, Seizures, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,50,M,75kg,MDR-TB,600mg,6 months,Anemia,Alcoholic,none,0,30,9,185,"GI Upset, Psychiatric Symptoms, Blood Disorders","Irritability, Anemia, Diarrhea, Nausea, Leukopenia, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,75,M,62kg,MDR-TB,600mg,6 months,Renal Disease,Alcoholic,none,0,36,18,165,"Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Isoniazid,71,F,69kg,XDR-TB,300mg,6-9 months,Hypertension,Occasional Smoker,none,0,38,10,160,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,29,M,100kg,XDR-TB,600mg,6 months,Renal Disease,Alcoholic,none,0,27,8,274,"GI Upset, Hepatotoxicity","Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,45,F,57kg,Tuberculosis,285mg,6-9 months,Anemia,none,none,0,32,12,157,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,50,F,36kg,Tuberculosis,360mg,6 months,none,none,yes,1,26,18,165,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Isoniazid,73,M,74kg,XDR-TB,300mg,6-9 months,Diabetes,Occasional Smoker,none,0,11,7,214,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Rifampicin,13,F,54kg,MDR-TB,540mg,6 months,Diabetes,Alcoholic,none,0,39,10,280,"Renal Toxicity, Hepatotoxicity","Hematuria, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Ethambutol,73,F,42kg,XDR-TB,383mg,6 months,HIV,Occasional Smoker,none,0,32,26,161,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,73,F,84kg,MDR-TB,600mg,6 months,Anemia,Alcoholic,none,0,32,24,251,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Rifampicin,80,F,62kg,Tuberculosis,600mg,6 months,Liver Disease,Smoker,none,0,16,28,161,"Renal Toxicity, Optic Neuritis, Blood Disorders","Hematuria, Anemia, Proteinuria, Kidney dysfunction, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,77,F,80kg,Tuberculosis,600mg,6 months,HIV,none,none,0,34,14,233,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Ethambutol,30,M,48kg,XDR-TB,402mg,6 months,Renal Disease,Smoker,none,0,32,20,212,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,77,F,99kg,MDR-TB,600mg,6 months,Anemia,Occasional Smoker,yes,6,17,10,236,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Pyrazinamide,35,M,97kg,Tuberculosis,411mg,8 months,HIV,Smoker,none,0,14,29,211,"GI Upset, Optic Neuritis, Psychiatric Symptoms","Irritability, Diarrhea, Nausea, Blurry vision, Abdominal pain, Depression, Vision loss, Hallucinations, Loss of appetite",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Rifampicin,13,F,77kg,MDR-TB,600mg,6 months,Hypertension,none,yes,1,23,16,241,"Optic Neuritis, Hepatotoxicity","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,69,F,76kg,XDR-TB,600mg,6 months,none,none,yes,5,16,27,168,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Rifampicin,64,F,92kg,XDR-TB,600mg,6 months,Renal Disease,Drug User,yes,2,34,26,272,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,67,F,71kg,Tuberculosis,315mg,10 months,Diabetes,none,yes,8,40,16,198,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Pyrazinamide,47,M,98kg,Tuberculosis,239mg,12 months,Anemia,Alcoholic,none,0,39,28,228,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,72,F,57kg,MDR-TB,250mg,10 months,Renal Disease,Drug User,yes,2,19,24,270,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,50,F,72kg,Tuberculosis,300mg,6-9 months,Anemia,Alcoholic,none,0,34,17,166,"Optic Neuritis, GI Upset","Diarrhea, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,27,F,61kg,XDR-TB,213mg,6 months,Renal Disease,Smoker,yes,2,30,25,274,"Hypersensitivity Reactions, Hepatotoxicity","Anaphylaxis, Jaundice, Joint pain, Vomiting, Nausea, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Skin rashes",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,80,F,34kg,MDR-TB,170mg,6-9 months,none,Drug User,none,0,38,28,172,"Hypersensitivity Reactions, Hepatotoxicity, Peripheral Neuropathy","Anaphylaxis, Jaundice, Joint pain, Burning sensation, Tingling, Vomiting, Nausea, Swelling, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Fever, Numbness, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,26,M,89kg,Tuberculosis,300mg,6-9 months,Renal Disease,Occasional Smoker,none,0,11,15,174,"Peripheral Neuropathy, Renal Toxicity, Hypersensitivity Reactions","Anaphylaxis, Hematuria, Tingling, Burning sensation, Joint pain, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Swelling, Fever, Numbness, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Isoniazid,43,M,91kg,MDR-TB,300mg,6-9 months,Renal Disease,Smoker,none,0,14,21,237,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,74,F,60kg,Tuberculosis,491mg,7 months,Renal Disease,Occasional Smoker,none,0,27,25,259,"GI Upset, CNS Effects, Hepatotoxicity","Psychosis, Headache, Seizures, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Vomiting, Confusion, Loss of appetite",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Ethambutol,55,M,73kg,MDR-TB,498mg,6 months,Anemia,Alcoholic,none,0,16,9,167,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,38,F,68kg,MDR-TB,258mg,6 months,Anemia,Alcoholic,yes,6,38,27,158,"Hepatotoxicity, GI Upset","Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,35,F,85kg,MDR-TB,600mg,6 months,Anemia,Occasional Smoker,none,0,10,19,192,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Isoniazid,56,F,52kg,XDR-TB,260mg,6-9 months,Hypertension,Alcoholic,yes,2,18,25,196,"Optic Neuritis, Blood Disorders","Anemia, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Rifampicin,21,F,64kg,XDR-TB,600mg,6 months,Anemia,Occasional Smoker,none,0,39,25,176,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,21,F,99kg,Tuberculosis,341mg,12 months,Hypertension,Drug User,yes,2,18,20,220,"Optic Neuritis, GI Upset, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Blurry vision, Abdominal pain, Fever, Skin rashes, Vision loss, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,23,M,51kg,MDR-TB,415mg,10 months,Renal Disease,Drug User,none,0,31,15,262,"GI Upset, Renal Toxicity, Optic Neuritis","Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Isoniazid,21,M,48kg,XDR-TB,240mg,6-9 months,Renal Disease,Occasional Smoker,none,0,36,17,209,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),none
Rifampicin,53,M,75kg,XDR-TB,600mg,6 months,Hypertension,none,none,0,16,15,192,"Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,19,M,79kg,XDR-TB,600mg,6 months,Liver Disease,Alcoholic,none,0,11,5,257,"Psychiatric Symptoms, Hypersensitivity Reactions, GI Upset","Anaphylaxis, Loss of appetite, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,70,F,84kg,Tuberculosis,600mg,6 months,Renal Disease,Smoker,yes,1,16,30,172,"Blood Disorders, Peripheral Neuropathy, Renal Toxicity","Anemia, Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Leukopenia, Weakness, Muscle cramps, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,54,M,40kg,Tuberculosis,200mg,6-9 months,Renal Disease,Drug User,none,0,27,30,215,"Hepatotoxicity, CNS Effects","Psychosis, Vomiting, Seizures, Headache, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Rifampicin,23,F,63kg,MDR-TB,600mg,6 months,Hypertension,Alcoholic,yes,8,31,23,248,"Renal Toxicity, Peripheral Neuropathy, Psychiatric Symptoms","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,26,F,53kg,XDR-TB,416mg,10 months,Liver Disease,Drug User,none,0,20,21,275,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,18,F,40kg,XDR-TB,250mg,8 months,HIV,Alcoholic,yes,5,26,29,233,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,14,F,71kg,Tuberculosis,300mg,6-9 months,HIV,none,none,0,12,11,221,"Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,16,M,43kg,MDR-TB,130mg,7 months,Hypertension,none,none,0,20,13,182,"Optic Neuritis, Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,25,F,40kg,MDR-TB,159mg,6 months,Renal Disease,Drug User,yes,3,21,12,164,"Renal Toxicity, Hepatotoxicity","Hematuria, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,26,F,44kg,Tuberculosis,220mg,6-9 months,HIV,Alcoholic,none,0,20,7,150,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Monitor liver function tests regularly; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,21,F,30kg,XDR-TB,300mg,6 months,Hypertension,none,none,0,30,12,235,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Ethambutol,49,M,96kg,XDR-TB,450mg,8 months,HIV,none,none,0,40,22,195,"Peripheral Neuropathy, CNS Effects, Optic Neuritis","Tingling, Burning sensation, Psychosis, Headache, Seizures, Muscle cramps, Weakness, Blurry vision, Dizziness, Numbness, Confusion, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,16,F,62kg,XDR-TB,230mg,6 months,Hypertension,Occasional Smoker,none,0,30,6,197,"Psychiatric Symptoms, Hepatotoxicity, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,49,F,34kg,XDR-TB,340mg,6 months,Diabetes,Smoker,yes,4,33,25,201,"Peripheral Neuropathy, Hepatotoxicity","Tingling, Burning sensation, Muscle cramps, Weakness, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Numbness, Vomiting",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Isoniazid,57,M,41kg,MDR-TB,205mg,6-9 months,Liver Disease,Smoker,none,0,35,12,210,"CNS Effects, Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Seizures, Headache, Swelling, Blurry vision, Dizziness, Fever, Skin rashes, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Ethambutol,50,M,57kg,XDR-TB,308mg,6 months,HIV,Drug User,none,0,35,23,207,"Peripheral Neuropathy, Optic Neuritis","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Ethambutol,74,F,30kg,MDR-TB,499mg,8 months,Hypertension,Smoker,yes,1,27,12,159,"CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Swelling, Dizziness, Fever, Skin rashes, Confusion",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,78,M,68kg,Tuberculosis,220mg,6 months,none,Occasional Smoker,none,0,28,19,205,"Hepatotoxicity, Renal Toxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,31,F,45kg,Tuberculosis,450mg,6 months,Renal Disease,none,none,0,38,18,182,"CNS Effects, Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Swelling, Blurry vision, Dizziness, Fever, Skin rashes, Confusion, Vision loss",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Ethambutol,64,M,93kg,Tuberculosis,456mg,11 months,Anemia,Alcoholic,none,0,29,28,189,"Blood Disorders, Hepatotoxicity, Peripheral Neuropathy","Anemia, Tingling, Burning sensation, Vomiting, Leukopenia, Nausea, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Numbness, Jaundice, Neutropenia",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,57,M,77kg,MDR-TB,317mg,11 months,Anemia,Occasional Smoker,none,0,20,14,218,"Renal Toxicity, Peripheral Neuropathy, GI Upset","Hematuria, Tingling, Burning sensation, Proteinuria, Diarrhea, Kidney dysfunction, Muscle cramps, Weakness, Nausea, Abdominal pain, Numbness, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,19,M,33kg,MDR-TB,330mg,6 months,none,none,none,0,36,29,240,"Hepatotoxicity, Optic Neuritis, Blood Disorders","Anemia, Vomiting, Nausea, Leukopenia, Elevated liver enzymes, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Ethambutol,20,M,96kg,Tuberculosis,210mg,12 months,HIV,Alcoholic,none,0,39,30,155,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,30,F,45kg,MDR-TB,332mg,11 months,Renal Disease,Occasional Smoker,none,0,26,7,193,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,44,F,37kg,Tuberculosis,336mg,8 months,Hypertension,none,none,0,40,27,196,"Psychiatric Symptoms, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,75,F,97kg,Tuberculosis,246mg,6 months,none,Smoker,yes,3,36,22,182,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,49,M,69kg,XDR-TB,135mg,10 months,HIV,Smoker,none,0,40,14,182,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,47,M,35kg,Tuberculosis,350mg,6 months,Anemia,Alcoholic,none,0,25,22,257,"Psychiatric Symptoms, Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Blurry vision, Depression, Fever, Skin rashes, Vision loss, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,54,M,98kg,MDR-TB,600mg,6 months,Liver Disease,none,none,0,38,25,157,"Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Isoniazid,37,F,78kg,MDR-TB,300mg,6-9 months,Diabetes,Alcoholic,Pregnant - 7 months,9,23,9,264,"Hepatotoxicity, Optic Neuritis","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,67,M,46kg,MDR-TB,230mg,6-9 months,HIV,Drug User,none,0,34,14,152,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,14,M,39kg,XDR-TB,195mg,6-9 months,Renal Disease,Drug User,none,0,11,6,178,"GI Upset, Optic Neuritis","Diarrhea, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,10,F,37kg,Tuberculosis,370mg,6 months,Hypertension,Smoker,none,0,14,20,209,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,50,F,83kg,Tuberculosis,237mg,9 months,Anemia,Smoker,yes,5,32,8,202,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Rifampicin,76,F,53kg,XDR-TB,530mg,6 months,Renal Disease,Smoker,yes,7,22,12,193,"CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Swelling, Dizziness, Fever, Skin rashes, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,34,M,48kg,XDR-TB,240mg,6-9 months,HIV,Occasional Smoker,none,0,28,26,151,"GI Upset, Renal Toxicity","Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,66,M,37kg,Tuberculosis,370mg,6 months,Hypertension,Alcoholic,none,0,16,19,244,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Ethambutol,12,M,99kg,Tuberculosis,381mg,8 months,Liver Disease,none,none,0,24,27,198,"GI Upset, CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Diarrhea, Nausea, Swelling, Abdominal pain, Dizziness, Fever, Skin rashes, Confusion, Loss of appetite",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,79,F,81kg,MDR-TB,476mg,7 months,Anemia,Smoker,yes,1,31,20,204,"Hepatotoxicity, GI Upset","Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,22,F,92kg,MDR-TB,542mg,6 months,Hypertension,none,none,0,31,24,157,"CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Seizures, Headache, Muscle cramps, Weakness, Dizziness, Numbness, Confusion",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,41,M,62kg,XDR-TB,207mg,9 months,HIV,Occasional Smoker,none,0,16,22,272,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Rifampicin,24,M,98kg,XDR-TB,600mg,6 months,Renal Disease,Smoker,none,0,16,14,221,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,42,M,72kg,Tuberculosis,431mg,9 months,Renal Disease,Alcoholic,none,0,17,22,244,"Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Ethambutol,69,M,57kg,MDR-TB,460mg,12 months,Hypertension,none,none,0,11,29,225,"Renal Toxicity, Optic Neuritis, Psychiatric Symptoms","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Depression, Vision loss, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Pyrazinamide,33,F,49kg,XDR-TB,302mg,10 months,none,Drug User,none,0,20,13,150,"Optic Neuritis, Psychiatric Symptoms","Blurry vision, Vision loss, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Ethambutol,55,F,61kg,MDR-TB,162mg,9 months,Renal Disease,Drug User,none,0,19,22,216,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Isoniazid,20,F,86kg,MDR-TB,300mg,6-9 months,Anemia,none,yes,7,32,24,177,"Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,23,M,75kg,MDR-TB,600mg,6 months,none,Alcoholic,none,0,35,27,193,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,18,F,57kg,Tuberculosis,125mg,7 months,Renal Disease,Smoker,yes,2,37,25,223,"Hepatotoxicity, CNS Effects","Psychosis, Vomiting, Seizures, Headache, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Ethambutol,11,F,71kg,MDR-TB,211mg,12 months,Anemia,Alcoholic,Pregnant - 7 months,4,19,18,217,"Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Joint pain, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Isoniazid,24,M,38kg,MDR-TB,190mg,6-9 months,none,Alcoholic,none,0,34,18,260,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,62,F,52kg,XDR-TB,520mg,6 months,HIV,none,none,0,37,11,173,"Hepatotoxicity, Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Joint pain, Vomiting, Nausea, Swelling, Elevated liver enzymes, Blurry vision, Abdominal pain, Vision loss, Fever, Jaundice, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,27,M,73kg,XDR-TB,600mg,6 months,Hypertension,Alcoholic,none,0,39,23,186,"GI Upset, Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Diarrhea, Nausea, Leukopenia, Swelling, Abdominal pain, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,79,F,94kg,Tuberculosis,600mg,6 months,HIV,none,none,0,28,8,160,"Hepatotoxicity, Peripheral Neuropathy","Tingling, Burning sensation, Vomiting, Nausea, Weakness, Muscle cramps, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Rifampicin,38,F,88kg,XDR-TB,600mg,6 months,none,Occasional Smoker,none,0,25,13,208,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,20,M,43kg,XDR-TB,295mg,9 months,Liver Disease,Drug User,none,0,16,17,183,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,71,M,85kg,Tuberculosis,600mg,6 months,none,Alcoholic,none,0,16,21,224,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,20,F,74kg,Tuberculosis,389mg,6 months,Diabetes,Alcoholic,none,0,38,16,242,"CNS Effects, Psychiatric Symptoms, Renal Toxicity","Hematuria, Psychosis, Headache, Seizures, Proteinuria, Kidney dysfunction, Dizziness, Confusion, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Isoniazid,19,M,73kg,MDR-TB,300mg,6-9 months,Renal Disease,none,none,0,32,17,158,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,41,M,50kg,XDR-TB,500mg,6 months,Liver Disease,Occasional Smoker,none,0,18,12,196,"Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,77,F,38kg,XDR-TB,118mg,11 months,none,Smoker,none,0,24,5,161,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,43,F,42kg,MDR-TB,382mg,9 months,Diabetes,none,none,0,23,11,210,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,66,M,86kg,MDR-TB,533mg,11 months,Diabetes,Alcoholic,none,0,12,28,207,"Blood Disorders, Renal Toxicity, Hypersensitivity Reactions","Anaphylaxis, Anemia, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,53,M,88kg,MDR-TB,550mg,6 months,HIV,Smoker,none,0,35,29,160,"Hepatotoxicity, Blood Disorders, Psychiatric Symptoms","Anemia, Vomiting, Nausea, Leukopenia, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Isoniazid,32,M,100kg,MDR-TB,300mg,6-9 months,HIV,Drug User,none,0,14,23,188,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Ethambutol,18,M,51kg,XDR-TB,395mg,8 months,HIV,Smoker,none,0,31,9,164,"Psychiatric Symptoms, Optic Neuritis","Blurry vision, Depression, Vision loss, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Ethambutol,60,F,49kg,XDR-TB,507mg,11 months,Diabetes,none,yes,1,10,14,276,"Optic Neuritis, Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,65,M,34kg,MDR-TB,340mg,6 months,Liver Disease,Smoker,none,0,22,17,251,"Renal Toxicity, Hypersensitivity Reactions","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,67,F,56kg,MDR-TB,560mg,6 months,Diabetes,Occasional Smoker,yes,2,18,21,201,"Renal Toxicity, Hypersensitivity Reactions","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,73,F,75kg,XDR-TB,501mg,9 months,Liver Disease,Alcoholic,yes,2,25,22,242,"Blood Disorders, Renal Toxicity, Optic Neuritis","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Pyrazinamide,46,M,32kg,Tuberculosis,215mg,9 months,Diabetes,Occasional Smoker,none,0,39,11,154,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,28,M,94kg,MDR-TB,175mg,10 months,Hypertension,Occasional Smoker,none,0,14,10,216,"Peripheral Neuropathy, CNS Effects, Renal Toxicity","Hematuria, Tingling, Burning sensation, Psychosis, Headache, Seizures, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Dizziness, Numbness, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,15,F,92kg,XDR-TB,300mg,6-9 months,HIV,Smoker,yes,4,22,29,179,"GI Upset, Peripheral Neuropathy","Tingling, Burning sensation, Diarrhea, Nausea, Weakness, Muscle cramps, Abdominal pain, Numbness, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,44,F,75kg,Tuberculosis,600mg,6 months,none,Alcoholic,none,0,26,24,174,"Hepatotoxicity, Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Vomiting, Nausea, Muscle cramps, Weakness, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Numbness, Jaundice, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Ethambutol,23,M,88kg,Tuberculosis,532mg,7 months,Diabetes,Occasional Smoker,none,0,28,26,211,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,69,M,59kg,XDR-TB,131mg,7 months,Diabetes,Smoker,none,0,39,8,201,"Hepatotoxicity, Renal Toxicity, Psychiatric Symptoms","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,12,F,79kg,Tuberculosis,600mg,6 months,Renal Disease,Drug User,yes,8,17,10,241,"CNS Effects, Hepatotoxicity","Psychosis, Vomiting, Headache, Seizures, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,19,F,99kg,XDR-TB,300mg,6-9 months,Anemia,Alcoholic,none,0,32,17,233,"CNS Effects, Optic Neuritis","Psychosis, Headache, Seizures, Blurry vision, Dizziness, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Isoniazid,30,F,30kg,XDR-TB,150mg,6-9 months,Liver Disease,Drug User,none,0,35,22,184,"GI Upset, CNS Effects, Blood Disorders","Anemia, Psychosis, Seizures, Headache, Diarrhea, Thrombocytopenia, Nausea, Leukopenia, Neutropenia, Abdominal pain, Eosinophilia, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Isoniazid,13,F,86kg,MDR-TB,300mg,6-9 months,Liver Disease,Smoker,none,0,12,9,247,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Isoniazid,77,M,84kg,MDR-TB,300mg,6-9 months,none,Alcoholic,none,0,21,7,273,"CNS Effects, Hepatotoxicity","Psychosis, Seizures, Headache, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Vomiting, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,79,F,69kg,Tuberculosis,300mg,6-9 months,Anemia,Smoker,yes,2,28,12,151,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,15,F,61kg,Tuberculosis,161mg,7 months,Hypertension,Drug User,none,0,20,15,245,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,67,F,61kg,XDR-TB,600mg,6 months,HIV,Alcoholic,none,0,16,6,255,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Rifampicin,70,M,100kg,MDR-TB,600mg,6 months,Renal Disease,Occasional Smoker,none,0,22,16,260,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,15,F,95kg,MDR-TB,132mg,6 months,Diabetes,Alcoholic,yes,9,23,26,273,"Hepatotoxicity, Renal Toxicity, Optic Neuritis","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,11,M,79kg,Tuberculosis,600mg,6 months,HIV,Alcoholic,none,0,15,29,262,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Rifampicin,78,M,59kg,XDR-TB,590mg,6 months,HIV,Alcoholic,none,0,39,12,262,"Hypersensitivity Reactions, Peripheral Neuropathy, CNS Effects","Anaphylaxis, Joint pain, Burning sensation, Tingling, Psychosis, Headache, Seizures, Muscle cramps, Swelling, Weakness, Dizziness, Fever, Numbness, Skin rashes, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,50,M,57kg,MDR-TB,570mg,6 months,HIV,Alcoholic,none,0,23,21,205,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,54,M,45kg,XDR-TB,450mg,6 months,Anemia,Alcoholic,none,0,40,10,181,"GI Upset, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,29,M,82kg,XDR-TB,600mg,6 months,Anemia,Smoker,none,0,33,22,182,"Hepatotoxicity, Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Ethambutol,32,M,76kg,XDR-TB,174mg,9 months,HIV,none,none,0,19,5,228,"CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Seizures, Headache, Swelling, Dizziness, Fever, Skin rashes, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,56,F,40kg,XDR-TB,400mg,6 months,HIV,Smoker,yes,9,19,21,183,"Hepatotoxicity, Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Jaundice, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Pyrazinamide,80,F,35kg,MDR-TB,559mg,6 months,Liver Disease,Alcoholic,none,0,13,6,216,"Blood Disorders, CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Psychosis, Headache, Seizures, Leukopenia, Swelling, Confusion, Eosinophilia, Thrombocytopenia, Fever, Dizziness, Skin rashes, Neutropenia",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,22,M,92kg,XDR-TB,600mg,6 months,Anemia,Smoker,none,0,35,14,195,"Blood Disorders, Renal Toxicity, Psychiatric Symptoms","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,43,F,79kg,Tuberculosis,426mg,11 months,Renal Disease,Drug User,Pregnant - 7 months,1,22,11,183,Optic Neuritis,"Blurry vision, Vision loss",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Pyrazinamide,32,M,46kg,XDR-TB,481mg,12 months,Liver Disease,Occasional Smoker,none,0,13,14,230,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,18,F,69kg,MDR-TB,390mg,12 months,HIV,Drug User,none,0,32,8,157,"Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Ethambutol,74,F,89kg,XDR-TB,271mg,12 months,Liver Disease,Smoker,none,0,10,19,230,"Renal Toxicity, Blood Disorders","Hematuria, Anemia, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,41,M,70kg,MDR-TB,300mg,6-9 months,HIV,Drug User,none,0,27,30,208,"Peripheral Neuropathy, Renal Toxicity, Psychiatric Symptoms","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Isoniazid,32,F,49kg,MDR-TB,245mg,6-9 months,Renal Disease,Occasional Smoker,yes,1,25,13,220,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,59,M,57kg,MDR-TB,285mg,6-9 months,Diabetes,none,none,0,10,26,174,"Optic Neuritis, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Vision loss",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,15,F,86kg,XDR-TB,240mg,12 months,HIV,none,none,0,18,18,262,"Renal Toxicity, Hypersensitivity Reactions, Psychiatric Symptoms","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,34,M,74kg,XDR-TB,361mg,11 months,HIV,Occasional Smoker,none,0,36,15,233,"Peripheral Neuropathy, Blood Disorders, Optic Neuritis","Anemia, Tingling, Burning sensation, Muscle cramps, Weakness, Leukopenia, Blurry vision, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,47,F,56kg,XDR-TB,401mg,12 months,Hypertension,Alcoholic,Pregnant - 7 months,5,14,15,276,"Psychiatric Symptoms, Blood Disorders, Hepatotoxicity","Anemia, Vomiting, Leukopenia, Nausea, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,64,M,41kg,Tuberculosis,410mg,6 months,Diabetes,Occasional Smoker,none,0,19,26,248,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Ethambutol,47,F,87kg,XDR-TB,523mg,9 months,HIV,Occasional Smoker,yes,1,39,28,183,"Optic Neuritis, Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Blurry vision, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,42,M,39kg,XDR-TB,390mg,6 months,Diabetes,Alcoholic,none,0,35,16,214,"Psychiatric Symptoms, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Isoniazid,28,M,46kg,Tuberculosis,230mg,6-9 months,Diabetes,Occasional Smoker,none,0,37,11,257,"GI Upset, Renal Toxicity","Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Pyrazinamide,31,M,79kg,XDR-TB,106mg,8 months,Renal Disease,Alcoholic,none,0,15,30,264,"Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,64,M,45kg,MDR-TB,246mg,11 months,none,Drug User,none,0,39,23,264,Optic Neuritis,"Blurry vision, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,11,M,91kg,Tuberculosis,327mg,9 months,HIV,none,none,0,15,16,185,"Optic Neuritis, GI Upset","Diarrhea, Nausea, Blurry vision, Abdominal pain, Vision loss, Loss of appetite",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,19,M,64kg,XDR-TB,300mg,6-9 months,none,Drug User,none,0,13,11,180,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,40,M,34kg,XDR-TB,367mg,6 months,Diabetes,none,none,0,11,18,219,Optic Neuritis,"Blurry vision, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,66,M,78kg,XDR-TB,183mg,11 months,Liver Disease,Drug User,none,0,22,19,208,"Hepatotoxicity, Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Jaundice, Skin rashes",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,22,F,76kg,Tuberculosis,300mg,6-9 months,Hypertension,Occasional Smoker,none,0,15,9,156,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,43,F,74kg,XDR-TB,568mg,9 months,Hypertension,Occasional Smoker,yes,3,10,19,234,"GI Upset, CNS Effects, Hepatotoxicity","Psychosis, Vomiting, Headache, Seizures, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Ethambutol,31,F,48kg,MDR-TB,547mg,12 months,Liver Disease,Alcoholic,none,0,12,19,154,"Blood Disorders, Hepatotoxicity","Anemia, Leukopenia, Nausea, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Vomiting, Neutropenia",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Rifampicin,40,F,42kg,XDR-TB,420mg,6 months,none,none,none,0,40,24,248,"Blood Disorders, GI Upset, CNS Effects","Anemia, Psychosis, Headache, Seizures, Diarrhea, Leukopenia, Nausea, Confusion, Abdominal pain, Eosinophilia, Thrombocytopenia, Dizziness, Neutropenia, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,34,M,88kg,MDR-TB,300mg,6-9 months,Renal Disease,none,none,0,33,13,277,"Hypersensitivity Reactions, CNS Effects, GI Upset","Anaphylaxis, Joint pain, Psychosis, Headache, Seizures, Diarrhea, Nausea, Swelling, Abdominal pain, Dizziness, Fever, Skin rashes, Confusion, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Ethambutol,45,M,53kg,MDR-TB,216mg,11 months,none,none,none,0,27,14,202,"Hepatotoxicity, Renal Toxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Isoniazid,46,F,94kg,XDR-TB,300mg,6-9 months,Hypertension,Occasional Smoker,none,0,13,21,253,"Psychiatric Symptoms, Renal Toxicity, GI Upset","Hematuria, Loss of appetite, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,53,F,42kg,XDR-TB,233mg,8 months,HIV,Drug User,yes,6,24,9,251,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,18,M,53kg,Tuberculosis,332mg,10 months,Anemia,none,none,0,18,7,251,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,20,M,96kg,MDR-TB,536mg,9 months,Anemia,Drug User,none,0,18,10,181,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,67,M,56kg,Tuberculosis,489mg,10 months,Anemia,Occasional Smoker,none,0,11,24,228,"GI Upset, Blood Disorders","Anemia, Diarrhea, Leukopenia, Nausea, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,31,M,61kg,MDR-TB,300mg,6-9 months,Diabetes,Drug User,none,0,23,14,154,"CNS Effects, GI Upset","Psychosis, Seizures, Headache, Diarrhea, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,NAT2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,76,F,93kg,Tuberculosis,300mg,6-9 months,HIV,Occasional Smoker,yes,5,34,5,207,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,65,F,65kg,MDR-TB,300mg,6-9 months,Anemia,none,none,0,23,26,203,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Isoniazid,24,F,33kg,XDR-TB,165mg,6-9 months,Liver Disease,Drug User,none,0,38,6,213,"Hepatotoxicity, Blood Disorders","Anemia, Vomiting, Nausea, Leukopenia, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,55,F,44kg,XDR-TB,220mg,6-9 months,Hypertension,Occasional Smoker,yes,5,24,13,180,"Peripheral Neuropathy, Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Numbness, Skin rashes, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Pyrazinamide,70,M,66kg,MDR-TB,445mg,8 months,Diabetes,Smoker,none,0,16,13,202,"Psychiatric Symptoms, Blood Disorders","Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,56,F,91kg,XDR-TB,553mg,11 months,none,Alcoholic,none,0,39,21,177,"GI Upset, CNS Effects","Psychosis, Seizures, Headache, Diarrhea, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Isoniazid,59,M,68kg,Tuberculosis,300mg,6-9 months,Anemia,Drug User,none,0,11,9,280,"Renal Toxicity, GI Upset, CNS Effects","Hematuria, Psychosis, Seizures, Proteinuria, Headache, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Rifampicin,57,M,76kg,Tuberculosis,600mg,6 months,none,Occasional Smoker,none,0,39,6,249,"Peripheral Neuropathy, Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,65,M,97kg,Tuberculosis,300mg,6-9 months,Liver Disease,Occasional Smoker,none,0,20,20,178,"Optic Neuritis, CNS Effects, Blood Disorders","Anemia, Psychosis, Seizures, Headache, Thrombocytopenia, Leukopenia, Neutropenia, Blurry vision, Eosinophilia, Dizziness, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Ethambutol,64,M,33kg,XDR-TB,113mg,10 months,Anemia,Occasional Smoker,none,0,17,16,163,"GI Upset, Psychiatric Symptoms, Optic Neuritis","Loss of appetite, Diarrhea, Nausea, Blurry vision, Abdominal pain, Vision loss, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Pyrazinamide,46,F,33kg,XDR-TB,121mg,6 months,Renal Disease,Alcoholic,yes,2,10,8,224,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Isoniazid,77,F,57kg,Tuberculosis,285mg,6-9 months,Anemia,Alcoholic,none,0,33,22,226,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Monitor liver function tests regularly; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Rifampicin,79,F,34kg,Tuberculosis,340mg,6 months,Renal Disease,Smoker,yes,5,33,25,176,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Isoniazid,58,F,43kg,MDR-TB,215mg,6-9 months,HIV,Smoker,none,0,28,20,273,"Peripheral Neuropathy, CNS Effects","Tingling, Burning sensation, Psychosis, Seizures, Headache, Muscle cramps, Weakness, Dizziness, Numbness, Confusion",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Ethambutol,45,F,51kg,MDR-TB,452mg,11 months,Hypertension,none,none,0,19,29,229,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,78,M,77kg,MDR-TB,300mg,6-9 months,Liver Disease,none,none,0,20,22,265,"GI Upset, Renal Toxicity, CNS Effects","Hematuria, Psychosis, Seizures, Proteinuria, Headache, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Rifampicin,20,F,75kg,XDR-TB,600mg,6 months,none,Alcoholic,none,0,37,9,242,"Hypersensitivity Reactions, GI Upset, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,53,M,35kg,MDR-TB,350mg,6 months,Anemia,Drug User,none,0,11,10,258,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,25,F,61kg,Tuberculosis,371mg,12 months,Diabetes,Drug User,yes,6,39,17,217,"Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,15,M,98kg,XDR-TB,600mg,6 months,HIV,Drug User,none,0,11,30,254,"Psychiatric Symptoms, GI Upset","Irritability, Diarrhea, Nausea, Abdominal pain, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,55,F,95kg,XDR-TB,300mg,6-9 months,Liver Disease,Occasional Smoker,none,0,14,17,191,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,44,F,98kg,MDR-TB,600mg,6 months,none,none,none,0,30,10,215,"Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Fever, Numbness, Skin rashes",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Pyrazinamide,40,F,49kg,XDR-TB,409mg,8 months,none,Drug User,none,0,37,13,217,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,32,F,69kg,Tuberculosis,600mg,6 months,Liver Disease,Occasional Smoker,Pregnant - 7 months,7,34,7,196,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,14,M,75kg,XDR-TB,600mg,6 months,Renal Disease,none,none,0,39,8,240,"CNS Effects, Renal Toxicity","Hematuria, Psychosis, Headache, Seizures, Proteinuria, Kidney dysfunction, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,15,F,53kg,MDR-TB,537mg,7 months,Hypertension,Occasional Smoker,none,0,36,11,263,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,11,F,69kg,XDR-TB,600mg,6 months,Liver Disease,Occasional Smoker,none,0,29,6,181,"Hepatotoxicity, Renal Toxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,57,M,46kg,Tuberculosis,278mg,11 months,Renal Disease,none,none,0,37,27,234,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,53,F,45kg,XDR-TB,223mg,12 months,Hypertension,Alcoholic,yes,1,12,5,260,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Pyrazinamide,34,F,68kg,XDR-TB,539mg,12 months,Renal Disease,Drug User,none,0,31,16,221,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Ethambutol,71,M,96kg,Tuberculosis,448mg,12 months,Anemia,Occasional Smoker,none,0,34,27,168,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Pyrazinamide,26,M,76kg,XDR-TB,242mg,7 months,none,Drug User,none,0,40,7,175,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,68,M,45kg,Tuberculosis,501mg,7 months,Hypertension,Drug User,none,0,21,7,260,"Psychiatric Symptoms, Blood Disorders, Peripheral Neuropathy","Anemia, Tingling, Burning sensation, Leukopenia, Muscle cramps, Weakness, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Ethambutol,25,F,99kg,MDR-TB,313mg,11 months,Diabetes,Smoker,yes,1,12,25,250,"Blood Disorders, Psychiatric Symptoms, CNS Effects","Anemia, Psychosis, Headache, Seizures, Leukopenia, Confusion, Eosinophilia, Thrombocytopenia, Dizziness, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,22,M,83kg,MDR-TB,500mg,12 months,Diabetes,Occasional Smoker,none,0,22,21,253,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,25,M,67kg,Tuberculosis,395mg,9 months,Anemia,none,none,0,34,28,188,"GI Upset, Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Diarrhea, Nausea, Weakness, Muscle cramps, Swelling, Abdominal pain, Fever, Numbness, Skin rashes, Loss of appetite",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,34,F,65kg,XDR-TB,115mg,12 months,none,Smoker,yes,3,16,29,166,"Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),none
Rifampicin,70,F,51kg,MDR-TB,510mg,6 months,HIV,Smoker,none,0,37,18,279,"Psychiatric Symptoms, GI Upset","Irritability, Diarrhea, Nausea, Abdominal pain, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,58,F,65kg,Tuberculosis,579mg,12 months,Hypertension,Smoker,none,0,11,19,194,"CNS Effects, Optic Neuritis, Hepatotoxicity","Psychosis, Vomiting, Headache, Seizures, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Dizziness, Jaundice, Confusion, Vision loss",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,48,F,48kg,XDR-TB,480mg,6 months,Diabetes,Alcoholic,yes,2,18,14,257,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,50,F,43kg,MDR-TB,215mg,6-9 months,Liver Disease,Smoker,yes,5,10,8,261,"Hepatotoxicity, GI Upset, Peripheral Neuropathy","Tingling, Burning sensation, Vomiting, Diarrhea, Nausea, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,53,F,90kg,MDR-TB,301mg,8 months,none,Alcoholic,yes,9,40,10,174,"Psychiatric Symptoms, GI Upset, Renal Toxicity","Irritability, Hematuria, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Isoniazid,40,F,79kg,XDR-TB,300mg,6-9 months,none,Drug User,yes,7,15,22,152,"Blood Disorders, GI Upset, Optic Neuritis","Anemia, Diarrhea, Leukopenia, Nausea, Blurry vision, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Vision loss, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,42,F,78kg,Tuberculosis,171mg,7 months,Renal Disease,Alcoholic,yes,5,34,29,259,"CNS Effects, Renal Toxicity","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Dizziness, Confusion",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Pyrazinamide,53,F,77kg,XDR-TB,331mg,6 months,Renal Disease,none,yes,3,34,9,177,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Pyrazinamide,46,M,32kg,Tuberculosis,542mg,12 months,Liver Disease,Alcoholic,none,0,29,29,248,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,49,F,76kg,Tuberculosis,300mg,6-9 months,HIV,Alcoholic,yes,8,32,27,226,"Renal Toxicity, Optic Neuritis, Psychiatric Symptoms","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Depression, Vision loss, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,NAT2 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,22,M,31kg,XDR-TB,182mg,9 months,Anemia,Occasional Smoker,none,0,34,28,226,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,34,F,89kg,XDR-TB,300mg,6-9 months,Anemia,Smoker,none,0,34,12,243,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Pyrazinamide,30,M,61kg,Tuberculosis,357mg,9 months,none,Drug User,none,0,35,5,223,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,70,F,51kg,Tuberculosis,303mg,7 months,Hypertension,Occasional Smoker,Pregnant - 7 months,2,10,25,192,"Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Prednisolone
Ethambutol,11,F,71kg,Tuberculosis,303mg,12 months,HIV,Alcoholic,yes,6,34,21,167,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,26,F,31kg,XDR-TB,155mg,6-9 months,Renal Disease,Occasional Smoker,none,0,10,19,274,"Optic Neuritis, CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Headache, Seizures, Muscle cramps, Weakness, Blurry vision, Dizziness, Numbness, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,36,M,55kg,MDR-TB,305mg,6 months,Renal Disease,Drug User,none,0,17,13,239,"CNS Effects, Hepatotoxicity","Psychosis, Vomiting, Seizures, Headache, Nausea, Elevated liver enzymes, Abdominal pain, Dizziness, Jaundice, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,34,M,39kg,Tuberculosis,390mg,6 months,Liver Disease,none,none,0,18,29,206,"Renal Toxicity, Psychiatric Symptoms, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,24,M,73kg,MDR-TB,498mg,8 months,Anemia,Smoker,none,0,14,13,274,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Isoniazid,16,M,46kg,XDR-TB,230mg,6-9 months,Diabetes,Occasional Smoker,none,0,23,26,261,"Blood Disorders, Hypersensitivity Reactions","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Rifampicin,78,M,46kg,Tuberculosis,460mg,6 months,HIV,none,none,0,21,7,202,"Hypersensitivity Reactions, CNS Effects, Peripheral Neuropathy","Anaphylaxis, Joint pain, Burning sensation, Psychosis, Tingling, Seizures, Headache, Muscle cramps, Swelling, Weakness, Dizziness, Fever, Numbness, Skin rashes, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Pyrazinamide,21,M,70kg,XDR-TB,566mg,6 months,Hypertension,Drug User,none,0,10,24,271,"Renal Toxicity, Hepatotoxicity","Hematuria, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Rifampicin,74,F,59kg,Tuberculosis,590mg,6 months,Hypertension,Smoker,none,0,30,6,203,"Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Joint pain, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,43,F,68kg,Tuberculosis,337mg,11 months,Hypertension,Occasional Smoker,none,0,30,8,170,"Optic Neuritis, Peripheral Neuropathy","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,62,M,38kg,MDR-TB,190mg,6-9 months,Hypertension,Occasional Smoker,none,0,18,30,231,"CNS Effects, Renal Toxicity, GI Upset","Hematuria, Psychosis, Headache, Seizures, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Abdominal pain, Dizziness, Confusion, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,18,F,71kg,Tuberculosis,600mg,6 months,HIV,Occasional Smoker,none,0,30,28,203,"Hypersensitivity Reactions, CNS Effects","Anaphylaxis, Joint pain, Psychosis, Seizures, Headache, Swelling, Dizziness, Fever, Skin rashes, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Ethambutol,32,M,54kg,MDR-TB,221mg,12 months,none,Drug User,none,0,11,17,160,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,68,M,93kg,Tuberculosis,600mg,6 months,Liver Disease,none,none,0,25,26,271,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,21,F,99kg,MDR-TB,600mg,6 months,Liver Disease,Occasional Smoker,none,0,30,17,176,"CNS Effects, Renal Toxicity","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,68,F,60kg,XDR-TB,600mg,6 months,Hypertension,Smoker,none,0,24,20,160,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,15,F,90kg,XDR-TB,188mg,6 months,Liver Disease,Drug User,none,0,11,8,162,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,31,F,40kg,Tuberculosis,200mg,6-9 months,Diabetes,Drug User,yes,2,14,17,262,"Hypersensitivity Reactions, GI Upset","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,61,F,37kg,XDR-TB,370mg,6 months,HIV,Occasional Smoker,yes,3,23,11,250,"Peripheral Neuropathy, Optic Neuritis, GI Upset","Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Blurry vision, Abdominal pain, Numbness, Vision loss, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Pyrazinamide,41,M,72kg,MDR-TB,492mg,8 months,none,Drug User,none,0,19,23,280,Optic Neuritis,"Blurry vision, Vision loss",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Pyrazinamide,20,M,34kg,MDR-TB,442mg,8 months,Liver Disease,Drug User,none,0,20,22,251,"Hepatotoxicity, Optic Neuritis","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Pyrazinamide,28,M,77kg,Tuberculosis,447mg,8 months,Liver Disease,Occasional Smoker,none,0,40,13,217,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Assess for potential drug resistance; Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance,PNCA gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Isoniazid,67,F,76kg,XDR-TB,300mg,6-9 months,Anemia,Smoker,yes,8,27,6,155,"Psychiatric Symptoms, Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,11,F,68kg,MDR-TB,300mg,6-9 months,HIV,Occasional Smoker,none,0,34,12,198,"Blood Disorders, GI Upset, Psychiatric Symptoms","Anemia, Irritability, Diarrhea, Leukopenia, Nausea, Abdominal pain, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,40,M,64kg,MDR-TB,431mg,8 months,Anemia,Smoker,none,0,25,11,250,"Hepatotoxicity, Peripheral Neuropathy","Tingling, Burning sensation, Vomiting, Nausea, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,38,M,90kg,MDR-TB,600mg,6 months,HIV,none,none,0,30,17,264,"Peripheral Neuropathy, Blood Disorders, Psychiatric Symptoms","Anemia, Tingling, Burning sensation, Muscle cramps, Weakness, Leukopenia, Eosinophilia, Thrombocytopenia, Numbness, Neutropenia, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,39,M,94kg,XDR-TB,600mg,6 months,Diabetes,Smoker,none,0,17,18,242,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,11,M,88kg,MDR-TB,600mg,6 months,none,none,none,0,38,5,228,"Optic Neuritis, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Blurry vision, Fever, Skin rashes, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,66,F,69kg,XDR-TB,600mg,6 months,HIV,Drug User,Pregnant - 7 months,5,19,7,219,"Peripheral Neuropathy, GI Upset, Hepatotoxicity","Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Numbness, Vomiting, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,46,F,33kg,XDR-TB,142mg,9 months,Renal Disease,Alcoholic,yes,9,26,26,150,"Renal Toxicity, Peripheral Neuropathy","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Numbness",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,30,F,59kg,XDR-TB,590mg,6 months,none,Drug User,none,0,38,20,219,"Hypersensitivity Reactions, Psychiatric Symptoms","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Pyrazinamide,58,M,36kg,MDR-TB,259mg,10 months,Anemia,Occasional Smoker,none,0,17,25,266,"GI Upset, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Diarrhea, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection,ABCC2 polymorphism,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Isoniazid,51,M,96kg,Tuberculosis,300mg,6-9 months,HIV,Smoker,none,0,12,11,151,"Hepatotoxicity, Optic Neuritis","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,67,M,35kg,XDR-TB,455mg,11 months,Diabetes,Alcoholic,none,0,28,15,265,"Peripheral Neuropathy, GI Upset","Tingling, Burning sensation, Diarrhea, Muscle cramps, Weakness, Nausea, Abdominal pain, Numbness, Loss of appetite",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Pyrazinamide,27,M,75kg,Tuberculosis,354mg,8 months,HIV,Drug User,none,0,31,20,239,"Optic Neuritis, Psychiatric Symptoms","Blurry vision, Vision loss, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,37,F,61kg,Tuberculosis,600mg,6 months,Hypertension,Drug User,yes,7,29,17,153,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,17,M,81kg,MDR-TB,300mg,6-9 months,Anemia,none,none,0,16,8,202,"Hypersensitivity Reactions, Peripheral Neuropathy, GI Upset","Anaphylaxis, Joint pain, Burning sensation, Tingling, Diarrhea, Muscle cramps, Swelling, Weakness, Nausea, Abdominal pain, Fever, Numbness, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Isoniazid,62,M,81kg,MDR-TB,300mg,6-9 months,none,Drug User,none,0,33,23,179,"Optic Neuritis, CNS Effects, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Psychosis, Seizures, Headache, Swelling, Blurry vision, Dizziness, Fever, Skin rashes, Confusion, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,34,F,73kg,Tuberculosis,600mg,6 months,Anemia,Occasional Smoker,none,0,33,23,257,"Renal Toxicity, Psychiatric Symptoms","Hematuria, Proteinuria, Kidney dysfunction, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,24,M,90kg,Tuberculosis,600mg,6 months,Renal Disease,Drug User,none,0,18,9,192,"Hypersensitivity Reactions, Hepatotoxicity, Optic Neuritis","Anaphylaxis, Jaundice, Joint pain, Vomiting, Nausea, Swelling, Elevated liver enzymes, Blurry vision, Abdominal pain, Fever, Skin rashes, Vision loss",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Probiotics
Rifampicin,46,F,40kg,Tuberculosis,400mg,6 months,Diabetes,Alcoholic,none,0,15,7,154,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),none
Pyrazinamide,18,M,61kg,XDR-TB,505mg,12 months,HIV,Drug User,none,0,20,6,179,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Ethambutol,41,F,68kg,Tuberculosis,583mg,10 months,Hypertension,Smoker,none,0,18,20,186,"CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Headache, Seizures, Muscle cramps, Weakness, Dizziness, Numbness, Confusion",Perform regular eye exams to monitor for optic neuropathy; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Isoniazid,30,M,71kg,Tuberculosis,300mg,6-9 months,Liver Disease,none,none,0,10,26,204,"Blood Disorders, CNS Effects, Hepatotoxicity","Anemia, Psychosis, Vomiting, Seizures, Headache, Leukopenia, Nausea, Confusion, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Dizziness, Jaundice, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,23,M,49kg,Tuberculosis,490mg,6 months,Liver Disease,Occasional Smoker,none,0,17,25,167,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,45,F,43kg,Tuberculosis,215mg,6-9 months,Hypertension,Smoker,yes,7,17,14,217,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Statins
Pyrazinamide,49,F,74kg,XDR-TB,307mg,8 months,Hypertension,none,yes,6,10,23,215,"Psychiatric Symptoms, Hepatotoxicity, Peripheral Neuropathy","Tingling, Burning sensation, Vomiting, Nausea, Weakness, Muscle cramps, Elevated liver enzymes, Abdominal pain, Numbness, Jaundice, Depression, Hallucinations, Irritability",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,27,F,95kg,MDR-TB,600mg,6 months,Hypertension,Drug User,none,0,26,11,218,Optic Neuritis,"Blurry vision, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Pyrazinamide,56,M,31kg,XDR-TB,312mg,12 months,Liver Disease,none,none,0,40,7,188,"Renal Toxicity, Hepatotoxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Rifampicin,46,M,49kg,MDR-TB,490mg,6 months,Anemia,Occasional Smoker,none,0,27,19,166,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,72,M,43kg,XDR-TB,545mg,8 months,Liver Disease,Smoker,none,0,10,24,235,"Hypersensitivity Reactions, GI Upset, Peripheral Neuropathy","Anaphylaxis, Joint pain, Tingling, Burning sensation, Diarrhea, Nausea, Swelling, Weakness, Muscle cramps, Abdominal pain, Fever, Numbness, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,65,M,48kg,XDR-TB,240mg,6-9 months,Liver Disease,Smoker,none,0,26,27,183,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Ethambutol,39,F,42kg,MDR-TB,128mg,12 months,Liver Disease,Occasional Smoker,none,0,17,12,261,"Blood Disorders, Hypersensitivity Reactions, Optic Neuritis","Anaphylaxis, Anemia, Joint pain, Leukopenia, Swelling, Blurry vision, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Vision loss",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,22,M,41kg,Tuberculosis,410mg,6 months,Anemia,none,none,0,34,24,259,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),none
Ethambutol,36,M,71kg,XDR-TB,250mg,11 months,Renal Disease,none,none,0,32,29,151,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Rifampicin,49,M,53kg,XDR-TB,530mg,6 months,Diabetes,Occasional Smoker,none,0,33,24,252,"Hepatotoxicity, Optic Neuritis, Psychiatric Symptoms","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Depression, Jaundice, Vision loss, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Isoniazid,80,M,53kg,MDR-TB,265mg,6-9 months,Renal Disease,Occasional Smoker,none,0,37,22,152,"Hepatotoxicity, Renal Toxicity","Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Isoniazid,31,M,47kg,XDR-TB,235mg,6-9 months,HIV,Occasional Smoker,none,0,40,6,223,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Increased half-life,Standard therapeutic effect,Omeprazole (Altered metabolism),Statins
Isoniazid,69,F,82kg,XDR-TB,300mg,6-9 months,Renal Disease,Alcoholic,none,0,11,27,189,"Blood Disorders, Psychiatric Symptoms","Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,CYP2E1 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Omeprazole
Rifampicin,37,F,73kg,MDR-TB,600mg,6 months,HIV,Smoker,yes,8,38,25,242,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,80,F,33kg,XDR-TB,330mg,6 months,Renal Disease,Smoker,none,0,34,7,216,"CNS Effects, Optic Neuritis","Psychosis, Seizures, Headache, Blurry vision, Dizziness, Confusion, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Ethambutol,58,F,71kg,XDR-TB,516mg,11 months,Hypertension,Occasional Smoker,none,0,22,12,232,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Statins
Rifampicin,11,F,41kg,Tuberculosis,410mg,6 months,none,Drug User,none,0,37,15,221,"Renal Toxicity, Optic Neuritis","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Vision loss",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Statins
Ethambutol,76,F,37kg,Tuberculosis,562mg,10 months,none,Alcoholic,none,0,10,26,276,"CNS Effects, Psychiatric Symptoms, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Seizures, Headache, Muscle cramps, Weakness, Dizziness, Numbness, Confusion, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,52,M,63kg,MDR-TB,300mg,6-9 months,HIV,Drug User,none,0,30,30,220,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,NAT2 polymorphism,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Ethambutol,13,F,42kg,MDR-TB,314mg,8 months,none,Smoker,none,0,38,8,246,"Peripheral Neuropathy, Renal Toxicity, GI Upset","Hematuria, Tingling, Burning sensation, Proteinuria, Diarrhea, Kidney dysfunction, Muscle cramps, Weakness, Nausea, Abdominal pain, Numbness, Loss of appetite",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Perform regular eye exams to monitor for optic neuropathy; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Prednisolone
Rifampicin,39,M,59kg,MDR-TB,590mg,6 months,Renal Disease,Alcoholic,none,0,29,18,199,"Hypersensitivity Reactions, Blood Disorders, Peripheral Neuropathy","Anaphylaxis, Anemia, Joint pain, Burning sensation, Tingling, Leukopenia, Swelling, Muscle cramps, Weakness, Eosinophilia, Thrombocytopenia, Fever, Numbness, Skin rashes, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Ethambutol,74,M,92kg,MDR-TB,300mg,7 months,Hypertension,Occasional Smoker,none,0,31,19,238,"Hepatotoxicity, CNS Effects, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Vomiting, Headache, Seizures, Nausea, Muscle cramps, Weakness, Elevated liver enzymes, Abdominal pain, Dizziness, Numbness, Jaundice, Confusion",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Pyrazinamide,63,M,82kg,MDR-TB,179mg,8 months,Diabetes,Alcoholic,none,0,22,16,190,"Blood Disorders, Psychiatric Symptoms","Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia, Depression, Hallucinations, Irritability",Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,16,F,93kg,Tuberculosis,300mg,6-9 months,Diabetes,Drug User,Pregnant - 7 months,1,21,5,172,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),Omeprazole
Rifampicin,38,M,42kg,XDR-TB,420mg,6 months,none,Alcoholic,none,0,17,30,172,"Blood Disorders, Renal Toxicity","Anemia, Hematuria, Proteinuria, Kidney dysfunction, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,60,F,100kg,MDR-TB,600mg,6 months,Renal Disease,Drug User,yes,9,23,30,243,CNS Effects,"Psychosis, Headache, Seizures, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Pyrazinamide,15,M,33kg,MDR-TB,454mg,10 months,Diabetes,Alcoholic,none,0,10,11,261,"Hypersensitivity Reactions, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Kidney dysfunction, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,24,F,30kg,Tuberculosis,300mg,6 months,Renal Disease,Occasional Smoker,yes,1,39,23,226,"Psychiatric Symptoms, Hepatotoxicity, Renal Toxicity","Hematuria, Proteinuria, Kidney dysfunction, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Vomiting, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Reduced metabolism,Standard therapeutic effect,Omeprazole (Altered metabolism),Prednisolone
Rifampicin,42,F,42kg,XDR-TB,420mg,6 months,Renal Disease,Alcoholic,yes,7,37,26,150,"Optic Neuritis, Peripheral Neuropathy, Renal Toxicity","Hematuria, Tingling, Burning sensation, Proteinuria, Kidney dysfunction, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Ethambutol,79,M,72kg,Tuberculosis,296mg,7 months,Diabetes,Alcoholic,none,0,30,27,221,"Optic Neuritis, Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Blurry vision, Fever, Numbness, Skin rashes, Vision loss",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Ethambutol,52,F,71kg,MDR-TB,210mg,11 months,HIV,Alcoholic,none,0,23,28,231,"CNS Effects, Renal Toxicity","Hematuria, Psychosis, Seizures, Headache, Proteinuria, Kidney dysfunction, Dizziness, Confusion",Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Ethambutol,33,F,77kg,Tuberculosis,188mg,6 months,Liver Disease,Alcoholic,Pregnant - 7 months,2,37,25,166,"Hepatotoxicity, GI Upset, Optic Neuritis","Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Jaundice, Vision loss, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Probiotics
Rifampicin,51,M,100kg,Tuberculosis,600mg,6 months,HIV,Occasional Smoker,none,0,36,30,155,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,SLCO1B1 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,63,M,55kg,XDR-TB,550mg,6 months,Hypertension,none,none,0,26,16,197,"Renal Toxicity, CNS Effects","Hematuria, Psychosis, Seizures, Proteinuria, Headache, Kidney dysfunction, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Omeprazole
Rifampicin,31,F,58kg,XDR-TB,580mg,6 months,HIV,Occasional Smoker,yes,4,40,18,243,CNS Effects,"Psychosis, Seizures, Headache, Dizziness, Confusion",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A5 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),none
Isoniazid,34,F,87kg,XDR-TB,300mg,6-9 months,Hypertension,none,yes,2,15,29,264,"Psychiatric Symptoms, Renal Toxicity, Optic Neuritis","Hematuria, Proteinuria, Kidney dysfunction, Blurry vision, Vision loss, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Reduced metabolism,Standard therapeutic effect,Alcohol (Increased liver damage risk),Omeprazole
Ethambutol,27,M,91kg,Tuberculosis,392mg,11 months,Hypertension,Alcoholic,none,0,21,13,241,"Psychiatric Symptoms, Hypersensitivity Reactions","Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes, Depression, Hallucinations, Irritability",Ensure strict adherence to therapy to prevent resistance; Recommend alcohol cessation to prevent liver toxicity; Perform regular eye exams to monitor for optic neuropathy; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,44,M,66kg,MDR-TB,200mg,8 months,none,none,none,0,26,16,204,Optic Neuritis,"Blurry vision, Vision loss",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Rifampicin,58,F,93kg,MDR-TB,600mg,6 months,Anemia,Smoker,none,0,14,25,184,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Ethambutol,32,F,45kg,XDR-TB,241mg,7 months,none,Occasional Smoker,none,0,37,24,271,"Hypersensitivity Reactions, GI Upset, Renal Toxicity","Anaphylaxis, Hematuria, Joint pain, Proteinuria, Diarrhea, Kidney dysfunction, Nausea, Swelling, Abdominal pain, Fever, Skin rashes, Loss of appetite",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC29A4 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,17,M,62kg,XDR-TB,300mg,6-9 months,Diabetes,Alcoholic,none,0,32,20,182,"Hypersensitivity Reactions, Blood Disorders, GI Upset","Anaphylaxis, Anemia, Joint pain, Diarrhea, Leukopenia, Swelling, Nausea, Abdominal pain, Eosinophilia, Thrombocytopenia, Fever, Skin rashes, Neutropenia, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Probiotics
Rifampicin,70,F,98kg,XDR-TB,600mg,6 months,Liver Disease,Alcoholic,yes,3,26,19,183,"GI Upset, Hepatotoxicity, Psychiatric Symptoms","Irritability, Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Depression, Hallucinations, Loss of appetite",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Omeprazole (Altered metabolism),Statins
Isoniazid,41,F,43kg,MDR-TB,215mg,6-9 months,none,Alcoholic,none,0,27,29,278,"Hepatotoxicity, Optic Neuritis, Psychiatric Symptoms","Vomiting, Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Depression, Jaundice, Vision loss, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor closely for hepatotoxicity and adjust regimen if needed; Monitor liver function tests regularly; Consider molecular testing for resistance detection,SLCO1B1 mutation,Increased half-life,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Ethambutol,25,M,51kg,Tuberculosis,384mg,9 months,Hypertension,Occasional Smoker,none,0,17,19,210,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Advise smoking cessation to improve lung function; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC29A4 mutation,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Prednisolone
Ethambutol,69,F,84kg,Tuberculosis,447mg,9 months,Anemia,Drug User,yes,1,17,30,215,"Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Fever, Numbness, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Increased half-life,Standard therapeutic effect,NSAIDs (Increased GI bleeding risk),none
Ethambutol,18,F,51kg,Tuberculosis,165mg,7 months,Hypertension,Drug User,yes,3,23,28,210,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Ensure strict adherence to therapy to prevent resistance; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Higher risk of optic neuritisâ€”consider dose reduction; Consider directly observed therapy (DOT) for better compliance; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),none
Isoniazid,75,M,100kg,MDR-TB,300mg,6-9 months,Renal Disease,none,none,0,38,5,182,"Peripheral Neuropathy, Hypersensitivity Reactions","Anaphylaxis, Tingling, Burning sensation, Joint pain, Muscle cramps, Weakness, Swelling, Fever, Numbness, Skin rashes",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),none
Pyrazinamide,41,F,82kg,Tuberculosis,271mg,8 months,Renal Disease,Alcoholic,none,0,33,24,265,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Isoniazid,77,M,47kg,Tuberculosis,235mg,6-9 months,HIV,Drug User,none,0,29,7,164,"CNS Effects, Blood Disorders","Anemia, Psychosis, Seizures, Headache, Thrombocytopenia, Leukopenia, Neutropenia, Eosinophilia, Dizziness, Confusion",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Reduced metabolism,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Prednisolone
Isoniazid,21,F,79kg,MDR-TB,300mg,6-9 months,Anemia,none,Pregnant - 7 months,9,35,26,252,"CNS Effects, Hepatotoxicity, Peripheral Neuropathy","Tingling, Burning sensation, Psychosis, Vomiting, Headache, Seizures, Nausea, Weakness, Muscle cramps, Elevated liver enzymes, Abdominal pain, Dizziness, Numbness, Jaundice, Confusion",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Consider molecular testing for resistance detection,NAT2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Pyrazinamide,17,M,58kg,Tuberculosis,454mg,12 months,Anemia,Smoker,none,0,15,28,204,Peripheral Neuropathy,"Tingling, Burning sensation, Muscle cramps, Weakness, Numbness",Monitor uric acid levels to prevent hyperuricemia; Ensure strict adherence to therapy to prevent resistance; Consider directly observed therapy (DOT) for better compliance; Avoid in patients with severe liver disease,ABCC2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,NSAIDs (Increased GI bleeding risk),Omeprazole
Pyrazinamide,78,F,97kg,XDR-TB,379mg,7 months,Anemia,Drug User,none,0,15,9,197,"Hepatotoxicity, GI Upset","Vomiting, Diarrhea, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice, Loss of appetite",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),none
Ethambutol,35,M,48kg,MDR-TB,481mg,6 months,Anemia,Drug User,none,0,19,23,251,"Optic Neuritis, Psychiatric Symptoms, Hepatotoxicity","Nausea, Elevated liver enzymes, Blurry vision, Abdominal pain, Vision loss, Jaundice, Vomiting, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Reduced metabolism,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Prednisolone
Pyrazinamide,61,F,76kg,Tuberculosis,177mg,8 months,Renal Disease,Drug User,none,0,37,26,162,Blood Disorders,"Anemia, Leukopenia, Eosinophilia, Thrombocytopenia, Neutropenia",Ensure strict adherence to therapy to prevent resistance; Avoid in patients with severe liver disease; Monitor uric acid levels to prevent hyperuricemia; Provide adherence support and addiction counseling; Consider directly observed therapy (DOT) for better compliance,ABCC2 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Isoniazid,19,F,64kg,Tuberculosis,300mg,6-9 months,Anemia,Occasional Smoker,none,0,29,12,220,Psychiatric Symptoms,"Depression, Hallucinations, Irritability",Supplement with vitamin B6 to prevent neuropathy; Ensure strict adherence to therapy to prevent resistance; Advise smoking cessation to improve lung function; Monitor liver function tests regularly; Consider directly observed therapy (DOT) for better compliance,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Alcohol (Increased liver damage risk),Statins
Isoniazid,56,F,69kg,Tuberculosis,300mg,6-9 months,Diabetes,none,none,0,30,17,243,GI Upset,"Diarrhea, Abdominal pain, Nausea, Loss of appetite",Supplement with vitamin B6 to prevent neuropathy; Consider directly observed therapy (DOT) for better compliance; Ensure strict adherence to therapy to prevent resistance; Monitor liver function tests regularly,CYP2E1 polymorphism,Increased half-life,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,51,M,56kg,MDR-TB,560mg,6 months,none,none,none,0,32,9,220,"Peripheral Neuropathy, Optic Neuritis","Tingling, Burning sensation, Muscle cramps, Weakness, Blurry vision, Numbness, Vision loss",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Monitor for potential drug-drug interactions with CYP3A4; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Increased half-life,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Omeprazole
Ethambutol,44,F,36kg,MDR-TB,359mg,6 months,Anemia,Drug User,yes,9,33,20,162,Renal Toxicity,"Proteinuria, Hematuria, Kidney dysfunction",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection; Adjust dose in renal impairment,embB gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),none
Pyrazinamide,44,F,90kg,XDR-TB,202mg,11 months,Diabetes,Alcoholic,yes,8,17,20,230,Hypersensitivity Reactions,"Anaphylaxis, Joint pain, Swelling, Fever, Skin rashes",Assess for potential drug resistance; Avoid in patients with severe liver disease; Use combination therapy with second-line agents; Recommend alcohol cessation to prevent liver toxicity; Monitor uric acid levels to prevent hyperuricemia; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,PNCA gene mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Statins
Pyrazinamide,55,F,33kg,XDR-TB,326mg,9 months,Hypertension,Smoker,yes,3,18,22,234,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Consider molecular testing for resistance detection; Monitor uric acid levels to prevent hyperuricemia; Avoid in patients with severe liver disease,ABCC2 polymorphism,Increased half-life,Standard therapeutic effect,Alcohol (Increased liver damage risk),Probiotics
Rifampicin,52,M,39kg,MDR-TB,390mg,6 months,Diabetes,Alcoholic,none,0,28,5,231,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Recommend alcohol cessation to prevent liver toxicity; Monitor for potential drug-drug interactions with CYP3A4; Monitor closely for hepatotoxicity and adjust regimen if needed; Consider molecular testing for resistance detection,CYP3A4 polymorphism,Reduced metabolism,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Statins
Isoniazid,71,F,56kg,XDR-TB,280mg,6-9 months,Diabetes,none,yes,7,18,21,182,Hepatotoxicity,"Vomiting, Nausea, Elevated liver enzymes, Abdominal pain, Jaundice",Use combination therapy with second-line agents; Supplement with vitamin B6 to prevent neuropathy; Consider molecular testing for resistance detection; Monitor liver function tests regularly,CYP2E1 polymorphism,Hepatic metabolism alteration,Standard therapeutic effect,Omeprazole (Altered metabolism),Probiotics
Rifampicin,38,F,100kg,Tuberculosis,600mg,6 months,none,Occasional Smoker,none,0,28,8,275,"Hypersensitivity Reactions, Hepatotoxicity","Anaphylaxis, Jaundice, Joint pain, Vomiting, Nausea, Swelling, Elevated liver enzymes, Abdominal pain, Fever, Skin rashes",Ensure strict adherence to therapy to prevent resistance; Warn about red-orange urine discoloration; Adjust dose based on enzyme activity levels; Advise smoking cessation to improve lung function; Monitor for potential drug-drug interactions with CYP3A4; Consider directly observed therapy (DOT) for better compliance,CYP3A4 polymorphism,Hepatic metabolism alteration,Enhanced drug sensitivity,NSAIDs (Increased GI bleeding risk),Probiotics
Isoniazid,68,F,92kg,XDR-TB,300mg,6-9 months,none,Drug User,none,0,21,29,236,"Hepatotoxicity, Blood Disorders, Renal Toxicity","Anemia, Hematuria, Vomiting, Proteinuria, Kidney dysfunction, Nausea, Leukopenia, Elevated liver enzymes, Abdominal pain, Eosinophilia, Thrombocytopenia, Jaundice, Neutropenia",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,SLCO1B1 mutation,Hepatic metabolism alteration,Enhanced drug sensitivity,Alcohol (Increased liver damage risk),Statins
Ethambutol,33,M,55kg,MDR-TB,379mg,10 months,Diabetes,none,none,0,17,15,205,"Hypersensitivity Reactions, Psychiatric Symptoms, Optic Neuritis","Anaphylaxis, Joint pain, Swelling, Blurry vision, Vision loss, Fever, Skin rashes, Depression, Hallucinations, Irritability",Use combination therapy with second-line agents; Perform regular eye exams to monitor for optic neuropathy; Higher risk of optic neuritisâ€”consider dose reduction; Consider molecular testing for resistance detection; Adjust dose in renal impairment,SLC2A3 mutation,Hepatic metabolism alteration,Increased hepatotoxicity risk,Omeprazole (Altered metabolism),Omeprazole
Isoniazid,74,M,30kg,MDR-TB,150mg,6-9 months,HIV,Drug User,none,0,34,12,218,Optic Neuritis,"Blurry vision, Vision loss",Supplement with vitamin B6 to prevent neuropathy; Use combination therapy with second-line agents; Adjust dose for slow acetylators to prevent toxicity; Monitor liver function tests regularly; Provide adherence support and addiction counseling; Consider molecular testing for resistance detection,NAT2 polymorphism,Hepatic metabolism alteration,Increased hepatotoxicity risk,Alcohol (Increased liver damage risk),Prednisolone
"Rifampicin, Isoniazid, Pyrazinamide, Ethambutol", 45, M, 67kg, Pulmonary TB,  Standard HRZE Dose, 6 months," Diabetes, Hypertension", Smoker, none, 0, 38,22,230,"Hepatotoxicity, Peripheral Neuropathy, Hyperuricemia"," Fatigue, Jaundice, Tingling in Hands & Feet, Joint Pain"," Monitor liver enzymes,supplement with Vitamin B6 for neuropathy, hydrate well to manage uric acid buildup, adjust dosage if needed",none,"Absorbed in the small intestine", "metabolized in the liver" ,"Avoid alcohol,interacts with warfarin & antidiabetic drugs","Metformin,Amlodipine,Vitamin B6,Allopurinol"
"Rifampicin, Isoniazid, Ethambutol, Pyrazinamide",39,F,55kg,Pulmonary TB,Standard HRZE Dose, 6 months,"HIV,Liver Dysfunction", Non-Smoker, none,0,45,35,275,"Severe Hepatotoxicity, Anemia, Skin Rash","Jaundice, Nausea, Dark Urine, Weakness,hepatic clearance may be delayed","Regular liver function tests, supplement Iron for anemia, use alternative TB regimen if needed","NAT2 Slow Acetylator,UGT1A1 Mutation","Metabolized in the liver","NAT2 Slow Acetylators,UGT1A1 Mutation","Interacts with antiretroviral drugs (EFV, LPV/r)","Tenofovir, Efavirenz,Folic Acid"
"Ioniazid+Rifampicin",35,M,68kg,Pulmonary TB ,"150mg,300mg",6 months,Hypertension,Smoker,none,0,32,28,190,"Hepatotoxicity","Rash,Nausea,Mild Jaundice","Regular LFT monitoring,Avoid alcohol,Ensure proper hydration,Consider dose adjustment if toxicity worsens",none,Normal absorption,Rifampicin induces metabolism of drugs,Rifampicin reduces Î²-blocker effect,"Amlodipine, Vitamin B6"
"Isoniazid+Ethambutol",39,F,60kg,Extrapulmonary TB,"300mg,900mg",2-9 months,none,Non-smoker,yes,2,32,22,170,"Peripheral neuropathy,liver toxicity-common,Hepatitis,neurotoxicity,hypersensitivity-Severe,Optic Neuritis,joint pain-common,Visual impairment,allergic reactions-Serious","Tingling,numbness,burning sensation in hands/feet,Jaundice,dark urine,nausea,vomiting,fatigue,Blurred vision, difficulty in color differentiation (red-green),Redness, itching, swelling, fever,Pain in joints, swelling (esp. in gout-prone patients)","Regular eye check-ups,Dose adjustment if vision worsens,Vitamin B6 (Pyridoxine)supplementation,Monitor ALT, AST, ALP; stop if severe,Stop Ethambutol immediately if vision worsen,Antihistamines, discontinue if severe,NSAIDs for symptom relief",none,Moderate metabolism,Inhibits arabinosyl transferase,"Avoid alcohol,Adjust if vision issues occur","Folic Acid,Calcium"